<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">62155</article-id><article-id pub-id-type="doi">10.7554/eLife.62155</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-204172"><name><surname>Li</surname><given-names>Wenqing</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204173"><name><surname>Tran</surname><given-names>Virginia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204174"><name><surname>Shaked</surname><given-names>Iftach</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204175"><name><surname>Xue</surname><given-names>Belinda</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204176"><name><surname>Moore</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204177"><name><surname>Lightle</surname><given-names>Rhonda</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-12888"><name><surname>Kleinfeld</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9797-4722</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204178"><name><surname>Awad</surname><given-names>Issam A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-41575"><name><surname>Ginsberg</surname><given-names>Mark H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5685-5417</contrib-id><email>mhginsberg@ucsd.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Medicine, University of California, San Diego</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Physics, University of California, San Diego</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Neurovascular Surgery Program, Section of Neurosurgery, Department of Surgery, University of Chicago School of Medicine and Biological Sciences</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Section of Neurobiology, University of California San Diego</institution><addr-line><named-content content-type="city">La Jolla</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dejana</surname><given-names>Elisabetta</given-names></name><role>Reviewing Editor</role><aff><institution>FIRC Institute of Molecular Oncology Foundationtion (IFOM)</institution><country>Italy</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Morrisey</surname><given-names>Edward E</given-names></name><role>Senior Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>20</day><month>05</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e62155</elocation-id><history><date date-type="received" iso-8601-date="2020-08-15"><day>15</day><month>08</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-05-19"><day>19</day><month>05</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Li et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-62155-v3.pdf"/><abstract><p>Mosaic inactivation of <italic>CCM2</italic> in humans causes cerebral cavernous malformations (CCMs) containing adjacent dilated blood-filled multi-cavernous lesions. We used CRISPR-Cas9 mutagenesis to induce mosaic inactivation of zebrafish <italic>ccm2</italic> resulting in a novel lethal multi-cavernous lesion in the embryonic caudal venous plexus (CVP) caused by obstruction of blood flow by intraluminal pillars. These pillars mimic those that mediate intussusceptive angiogenesis; however, in contrast to the normal process, the pillars failed to fuse to split the pre-existing vessel in two. Abortive intussusceptive angiogenesis stemmed from mosaic inactivation of <italic>ccm2</italic> leading to patchy <italic>klf2a</italic> overexpression and resultant aberrant flow signaling. Surviving adult fish manifested histologically typical hemorrhagic CCM. Formation of mammalian CCM requires the flow-regulated transcription factor KLF2; fish CCM and the embryonic CVP lesion failed to form in <italic>klf2a</italic> null fish indicating a common pathogenesis with the mammalian lesion. These studies describe a zebrafish CCM model and establish a mechanism that can explain the formation of characteristic multi-cavernous lesions.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cerebral cavernous malformations</kwd><kwd>blood flow signaling</kwd><kwd>angiogenesis</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL 139947</award-id><principal-award-recipient><name><surname>Ginsberg</surname><given-names>Mark H</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NS 92521</award-id><principal-award-recipient><name><surname>Moore</surname><given-names>Thomas</given-names></name><name><surname>Lightle</surname><given-names>Rhonda</given-names></name><name><surname>Awad</surname><given-names>Issam A</given-names></name><name><surname>Ginsberg</surname><given-names>Mark H</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000025</institution-id><institution>National Institute of Mental Health</institution></institution-wrap></funding-source><award-id>R35 NS097265</award-id><principal-award-recipient><name><surname>Kleinfeld</surname><given-names>David</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 NS108472</award-id><principal-award-recipient><name><surname>Shaked</surname><given-names>Iftach</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Be Brave for Life</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Li</surname><given-names>Wenqing</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic studies reveal that mosaic inactivation of <italic>ccm2</italic> causes characteristic cerebral cavernous malformations in adult zebrafish and aberrant responses to blood flow that induce the formation of a lethal embryonic multi-cavernous venous malformation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cerebral cavernous malformationsÂ (CCMs) are central nervous systemÂ (CNS) vascular anomalies that lead to significant morbidity and mortality (<xref ref-type="bibr" rid="bib25">Leblanc et al., 2009</xref>). CCMs affectÂ ~1/200 humans and cause a lifelong risk of stroke and other neurological sequelae for which there is no pharmacological therapy. Heterozygous loss of function mutations of three CCM genes (<italic>KRIT1(CCM1)</italic>, <italic>CCM2</italic>, and <italic>PDCD10(CCM3)</italic>) are associated with development of venous capillary dysplasias with hemorrhage and increased vascular permeability (<xref ref-type="bibr" rid="bib33">Mikati et al., 2015</xref>) characteristic of CCM (<xref ref-type="bibr" rid="bib25">Leblanc et al., 2009</xref>). Heterozygous patients often exhibit a âsecond hitâ on the normal <italic>CCM</italic> allele in CCM endothelial cells (<xref ref-type="bibr" rid="bib2">Akers et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">McDonald et al., 2011</xref>) and loss of function of P53 or <italic>Msh2</italic>, genes that maintain genome stability, âsensitizeâ <italic>Krit1<sup>+/-</sup></italic> or <italic>Pdcd10<sup>+/-</sup></italic> mice for development of CCM. Thus, CCMs are likely to arise following mosaic inactivation of both alleles of a given CCM gene. Neonatal endothelial-specific inactivation of murine <italic>Krit1, Pdcd10 (Ccm3), or Ccm2</italic> results in cerebellar and retinal vascular lesions that resemble CCM (<xref ref-type="bibr" rid="bib3">Boulday et al., 2011</xref>; <xref ref-type="bibr" rid="bib5">Chan et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Jenny Zhou et al., 2016</xref>). Thus, human CCMs arise from venous capillaries as a consequence of mosaic inactivation of these genes in endothelial cells.</p><p>The most striking form of CCM are large complexes containing adjacent dilated blood-filled thin-walled vessels with surrounding hemosiderin deposition indicative of chronic bleeding. These are the lesions that are surgically resected either to relieve eitherÂ mass effects or recurrent bleeding and are therefore clinically relevant. The cellular mechanism whereby these hallmark multi-cavernous lesions form is unknown and we reasoned that the genetic and experimental accessibility of the zebrafish and the optical transparency of its embryos and larvaeÂ (<xref ref-type="bibr" rid="bib15">Gore et al., 2018</xref>) could enable in vivo analysis of CCM development. In particular, the fish is amenable to examination of genetic perturbations by study of mutant fish, CRISPR/Cas9 mutagenesis, or morpholino silencing (<xref ref-type="bibr" rid="bib45">Stainier et al., 2017</xref>). The zebrafish âheart of glassâ defect in cardiac development led to the discovery of HEG1 (a binding partner for KRIT1; <xref ref-type="bibr" rid="bib13">Gingras et al., 2012</xref>) and to the demonstration that loss of KRIT1 (<italic>santa</italic>) or its binding partner, CCM2 (<italic>valentine</italic>), produced an identical cardiac phenotype (<xref ref-type="bibr" rid="bib29">Mably et al., 2006</xref>). Importantly, neither mutation nor silencing of any of these genes have been reported to produce zebrafish CCM. Second, silencing of <italic>pdcd10</italic> does not produce either cardiac dilation or CCM in the fish (<xref ref-type="bibr" rid="bib51">Yoruk et al., 2012</xref>). Furthermore, there is compelling evidence that HEG1 mutations do not produce CCM in mice or humansÂ (<xref ref-type="bibr" rid="bib53">Zheng et al., 2014</xref>). These data indicate important differences between the consequences of deletion of these genes in the endocardium and in brain endothelial cells and underscore the need for a zebrafish model of authentic CCM.</p><p>Here, we used CRISPR-Cas9 mutagenesis of <italic>ccm2</italic> to recapitulate the mosaic inactivation of a CCM gene. We observed a highly penetrant novel phenotype in embryos. By 2 days post fertilization (dpf),Â ~30% of embryos developed striking segmental dilatation of the caudal vein associated with slowed blood flow and formation of multiple dilated contiguous blood-filled chambers. We show that these lesions are caused by the intraluminal extension of pillars that lead to physical obstruction of blood flow. These pillars resemble the first steps of intussusceptive angiogenesis; however, in contrast to the physiological process, these pillars fail to organize and fuse together to split the pre-existing vessel in two. We show that this process of abortive intussusceptive angiogenesis is due to mosaic inactivation of <italic>ccm2</italic> leading to aberrant flow signaling and that, as in CCMs, KLF2 transcription factors play an important role in the formation of these lesions. In addition, typical CCM formed in the brains of all surviving adult and juvenile fish. As in murine CCM models, KLF2 transcription factors played a key role in the pathogenesis of zebrafish CCMs. Thus, abortive intussusceptive angiogenesis, as a consequence of aberrant flow signaling, leads to formation of multi-cavernous venous lesions in zebrafish embryos that resemble human multi-cavernous CCM.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>ccm2</italic> CRISPR zebrafish embryos display segmental dilation of the caudal venous plexus</title><p>As noted above, although null mutations of <italic>krit1</italic> and <italic>ccm2</italic> result in cardiac dilation and some vascular abnormalities, CCMs have not been observed in zebrafishÂ (<xref ref-type="bibr" rid="bib29">Mably et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Renz et al., 2015</xref>). We reasoned because humans with CCM are mosaic for homozygous inactivation of <italic>CCM1</italic> or <italic>CCM2</italic>, that induction of such mosaicism using a CRISPR-Cas9 system (<xref ref-type="bibr" rid="bib1">Ablain et al., 2015</xref>) could result in lesion formation. To create a mosaic animal, we co-injected Cas9 mRNA and gRNAs targeting the <italic>ccm2</italic> gene in zebrafish embryos (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). As expected, both genomic DNA sequencing and whole mount in situ hybridization showed that <italic>ccm2</italic> was targeted in a variable mosaic pattern affecting all tissues (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1B and C</xref>). About half of these mosaic embryos displayed lethal cardiovascular defects.</p><p>The most prevalent lethal phenotype, observed inÂ ~30% of 2 dpf <italic>ccm2</italic> CRISPR embryos, was localized dilatation of the caudal venous plexus (CVP) associated with erythrocyte accumulation and sluggish blood flow (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>, <xref ref-type="video" rid="video1">Video 1</xref>). This phenotype was clearly demonstrated in <italic>Tg(fli1:EGFP)<sup>y1</sup></italic> and <italic>Tg(gata1:DsRed)<sup>sd2</sup></italic> embryos in which erythrocytes are labeled with DsRed and endothelial cells with EGFP (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). Examination of the dilated CVP revealed multiple large blood-filled chambers separated by thin-walled partitions that bore a resemblance to Stage 2 human multi-cavernous CCM (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) in contrast to the normal architecture of control embryos (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In addition,Â ~5% of <italic>ccm2</italic> CRISPR embryos also displayed dilated cranial vessels (CV) (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). We also noted expected phenotypes previously reported in <italic>ccm</italic>2 morphants and mutants (<xref ref-type="bibr" rid="bib29">Mably et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Renz et al., 2015</xref>), a small proportion (~10%) of <italic>ccm2</italic> CRISPR embryos exhibited both heart dilation at 2 dpf and increased branching of the subintestinal vein (SIV) at 3 dpf (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>). Co-administration of <italic>ccm2</italic> mRNA prevented both CVP dilation and heart dilation in <italic>ccm2</italic> CRISPR embryos (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) confirming that both phenotypes are due to <italic>ccm2</italic> loss. Notably, the dilated heart and CVP dilation appeared to be mutually exclusive, thatÂ is, in over 200 embryos analyzed, we never observed both phenotypes in a single <italic>ccm2</italic> CRISPR embryo. Thus, the localized CVP dilation was the most prevalent phenotype observed in 2 dpf <italic>ccm2</italic> CRISPR embryos in comparison to the cardiac and SIV phenotypes that characterize <italic>ccm2</italic> null and <italic>ccm2</italic> morphant embryos (<xref ref-type="fig" rid="fig1">Figure 1H</xref>;Â <xref ref-type="bibr" rid="bib29">Mably et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Renz et al., 2015</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>ccm2</italic> CRISPR zebrafish embryo display novel vascular phenotypes.</title><p>Endothelial cells and red blood cells were labeled by EGFP and DsRed respectively in double transgenic <italic>Tg(fli1:EGFP)<sup>y1</sup>;Tg(gata1:DsRed)<sup>sd2</sup></italic> embryos. (<bold>A</bold>) Red blood cells accumulate in dilated segments of the caudal vein of <italic>ccm2</italic> CRISPR fish at 2Â daysÂ post fertilization (dpf). (<bold>B</bold>) cas9 mRNA-injected control embryo. (<bold>C</bold>) <italic>ccm2</italic> CRISPR embryos showed accumulation of red blood cells and intraluminal endothelial cells in a dilated segment of caudal vein in contrast to a control embryo. Note: In this and all succeeding sagittal views, anterior is to the leftÂ (<bold>D</bold>). (<bold>E</bold>) <italic>ccm2</italic> CRISPR embryos occasionally showed dilations of cerebral veins, whereas control embryos (<bold>F</bold>) showed normal development of cerebral veins (<bold>F</bold>). MCeV: mid-cerebral vein, PMBC: primordial midbrain channel, PHBC: primordial hindbrain channel. (<bold>G</bold>) The dilated caudal venous plexusÂ (CVP) and heart of <italic>ccm2</italic> CRISPR embryos were rescued by ccm2 mRNA injection. p=0.0336 (dilated CVP), 0.0037 (dilated heart). p-Values were calculated using an unpaired two-tailed Studentâs t-test. (<bold>H</bold>) Phenotypic distribution of dilated heart, CVP, and cerebral veins (CV) in <italic>ccm2</italic> CRISPR embryos at 2Â dpf. p=0.0078 (dilated CVP), 0.0268 (dilated heart), 0.0041Â (dilated CV). p-Values were calculated using a paired two-tailed Studentâs t-test. Error bars indicate SD. Scale bar: 1 mm in A and B, and 100 Âµm in C through F.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title><italic>ccm2</italic> CRISPR zebrafish exhibit mosaic expression of CCM2.</title><p>(<bold>A</bold>) Outline of the experiment: cas9 mRNA and gRNAs targeting <italic>ccm2</italic> were co-injected into one-cell stage zebrafish embryos. (<bold>B</bold>) Sequencing showed that the Cas9 together with designed gRNA could successfully target <italic>ccm2</italic> and produce indels. PAM sequence (5â-AGG-3â) is indicated in a rectangle. Though the wild-type sequence is the top read in each downstream position, indicating existence of wild-type allele, multiple reads emerged downstream of the PAM in <italic>ccm2</italic> CRISPR embryos. (<bold>C</bold>) Whole mount in situ hybridization of 2Â daysÂ post fertilization (dpf) embryos showed <italic>ccm2</italic> CRISPR embryos displaying patchy loss of CCM2 expression.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig1-figsupp1-v3.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>ApproximatelyÂ 10% of <italic>ccm2</italic> CRISPR zebrafish embryos exhibited dilation of heart and increased branch points of subintestinal vein.</title><p>Microinjection was performed on <italic>Tg(fli1:EGFP) embryos.</italic> (<bold>A and B</bold>) Both atrium and ventricle were dilated inÂ ~10% of <italic>ccm2</italic> CRISPR embryos on 2Â daysÂ post fertilization (dpf) (<bold>A</bold>) compared with normal heart in control (<bold>B</bold>). The heart was outlined by dash lines. (<bold>C and D</bold>) Increased branch points were observed on 3Â dpf inÂ ~10% of <italic>ccm2</italic> CRISPR embryos indicated by arrows. Scale bar: 100 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig1-figsupp2-v3.tif"/></fig></fig-group><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-62155-video1.mp4"><label>Video 1.</label><caption><title>On 2Â daysÂ post fertilization (dpf), <italic>ccm2</italic> CRISPR embryo displayed cavernoma-like lesion in the tail.</title><p>Blood flow was slowed down in the lesion area that contained retained blood cells.</p></caption></media></sec><sec id="s2-2"><title>Abortive intussusceptive angiogenesis in the dilated CVP of ccm2 CRISPR embryos</title><p>We used confocal microscopy and three-dimensionalÂ (3D) reconstruction of the dilated area of the CVP in <italic>Tg(fli1:EGFP;gata1:DsRed)</italic> zebrafish to explore their underlying structural defect. We noted intraluminal endothelial pillars that partitioned the lumen (<xref ref-type="fig" rid="fig2">Figure 2A</xref> through C) of the dilated CVP. In contrast, as expected, a completely patent caudal and ventral vein lumen formed in control embryos (<xref ref-type="fig" rid="fig2">Figure 2D</xref> through F). Furthermore, the ventral vein, which normally forms by a combination of sprouting and intussusceptive angiogenesisÂ (<xref ref-type="bibr" rid="bib21">Karthik et al., 2018</xref>), was lost in the dilated area of the CVP (<xref ref-type="fig" rid="fig2">Figure 2A</xref> through F). Importantly, examination of 3D reconstructions of the vessel revealed that these pillars were associated with pits on the external surface of the dilated CVP (<xref ref-type="fig" rid="fig2">Figure 2G</xref> arrows), a hallmark of the initial phase of intussusceptive angiogenesis (<xref ref-type="bibr" rid="bib10">Djonov et al., 2003</xref>). In contrast to normal intussusceptive angiogenesis, wherein transluminal pillars ultimately fuse to divide vessels longitudinally into new daughter vessels (<xref ref-type="bibr" rid="bib10">Djonov et al., 2003</xref>), the intussusceptions observed in <italic>ccm2</italic> CRISPR embryos were not coordinately formed and failed to fuse resulting in a honeycombed lumen. This honeycombing created a lumen with multiple chambers filled with red blood cells (RBCs) associated with sluggish blood flow (<xref ref-type="fig" rid="fig2">Figure 2I</xref> through K, <xref ref-type="video" rid="video2">Videos 2</xref> and <xref ref-type="video" rid="video3">3</xref>), whereas patent lumens and normal blood flow were observed in control embryos (<xref ref-type="video" rid="video4">Video 4</xref>). Thus, in these mosaic <italic>ccm2</italic> null zebrafish, an expanded region of the CVP is formed by multiple dilated erythrocyte-filled chambers and is associated with evidence of incomplete intussusceptive angiogenesis.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Intravascular pillars honeycomb the lumen of the caudal vein in <italic>ccm2</italic> CRISPR embryos.</title><p>(<bold>AâF</bold>) XZ planes and three-dimensionalÂ (3D) projection along Y axis of Airyscan images revealed intraluminal endothelial pillars at 2Â daysÂ post fertilization (dpf) (<bold>AâC</bold>), whereas Cas9-injected control embryos displayed a normal patent lumen in both a dorsal and ventral caudal vein (<bold>DâF</bold>). Endothelial cells were labeled by EGFP in <italic>Tg(fli1:EGFP)</italic> embryos. Arrow, arrowhead, and asterisk indicated the dorsal aorta, dorsal vein, and ventral vein, respectively. (<bold>G and H</bold>) Ventral view of 3D reconstruction show the irregular surface of the dramatically dilated caudal vein segment in <italic>ccm2</italic> CRISPR embryo (<bold>G</bold>) and normal ventral vein (<bold>H</bold>). Arrows in G indicate small pits where the endothelial pillars originate. (<bold>IâK</bold>) Intraluminal view of 3D reconstruction of <italic>ccm2</italic> CRISPR embryo reveals the intraluminal pillars honeycombing the lumen and the accumulated red blood cells (<bold>I</bold>). Erythrocytes were not imaged in J to reveal pillars and the area within the box in (<bold>J</bold>) was magnified in (<bold>K</bold>), and arrowhead indicates the intravascular pillar. Endothelial cells and red blood cells were labeled by EGFP or DsRed respectively in <italic>Tg(fli1:EGFP)<sup>y1</sup>;Tg(gata1:DsRed)<sup>sd2</sup></italic> embryos. Scale bar: 20 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig2-v3.tif"/></fig><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-62155-video2.mp4"><label>Video 2.</label><caption><title>Three-dimensional exterior view of caudal venous plexusÂ (CVP) of 2Â daysÂ post fertilization (dpf) <italic>ccm2</italic> CRISPR embryo.</title><p>Note pits on the surface and that the CVP is partitioned into several dilated areas.</p></caption></media><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-62155-video3.mp4"><label>Video 3.</label><caption><title>Three-dimensional interior view of caudal venous plexusÂ (CVP) of 2Â daysÂ post fertilization (dpf) <italic>ccm2</italic> CRISPR embryo.</title><p>Note the endothelial pillars within the lumen and accumulated red blood cells.</p></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-62155-video4.mp4"><label>Video 4.</label><caption><title>Three-dimensional view of caudal venous plexusÂ (CVP) of 2Â daysÂ post fertilization (dpf) control embryo.</title></caption></media></sec><sec id="s2-3"><title>Ablation of intravascular pillars reverts the dilated CVP phenotype</title><p>The multiple dilated compartments and sluggish blood flow suggested that this phenotype could be due to obstruction of free flow of erythrocytes by the meshwork of intravascular pillars. In support of this idea, we observed that spontaneous regression of an existing pillar was accompanied by reduced dilation of the CVP (<xref ref-type="fig" rid="fig3">Figure 3A</xref> through D). In addition, the trapped erythrocytes began to circulate freely. This rapid relief of both vessel dilation and blood stagnation suggested that the aberrant pillars may form a physical barrier thus resulting in accumulation of erythrocytes in dilated cavernous structures. To directly test the role of obstruction by intravascular pillars in dilation, we used targeted short pulses of near-infrared laser light to sever the pillars, a technique that generates negligible heat transfer and collateral damage to neighboring tissues (<xref ref-type="bibr" rid="bib35">Nishimura et al., 2006</xref>). There was near instantaneous reduction of the dilated vessel diameter (93.4 Âµm) to near-normal dimensions (69.4 Âµm) in the example shown (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>, <xref ref-type="video" rid="video5">Video 5</xref>). In three such independent experiments, severing these pillars resulted in a 29 Â± 4% reduction in vessel diameter (p=0.0004, two-tailed t-test). Thus, the pillars are an underlying cause of the CVP dilation observed in <italic>ccm2</italic> CRISPR embryos.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Intravascular pillars obstruct blood flow leading to vessel dilation in <italic>ccm2</italic> CRISPR embryos.</title><p>(<bold>A</bold> through <bold>D</bold>) Time lapse images reveal spontaneous retraction of an intravascular pillar leading to re-entry of blood cells into circulation and reduced dilation of the caudal vein. Endothelial cells were labeled by mCherry, and their nucleus and some red blood cells were labeled by EGFP in the <italic>Tg(fli1:nEGFP)<sup>y7</sup>;Tg(kdrl:mcherryras)<sup>s896</sup></italic> embryos. The retracted pillar is outlined by dotted lines for emphasis. Note that pillar retraction and vessel dilation were temporally correlated. (<bold>E and F</bold>) Laser ablation of pillar reduced caudal venous plexusÂ (CVP) diameter. The diameter of the dilated vein (<bold>E</bold>) was reduced after ablation (<bold>F</bold>). Note the pillars indicated by arrows in (<bold>E</bold>) are gone after ablation in (<bold>F</bold>). Dashed line indicates the diameter of the vein before and after ablation. Scale bar: 50 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig3-v3.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Both <italic>ccm2</italic> null mutants and morphants displayed heart dilation but no caudal venous plexusÂ (CVP) dilation on 2Â daysÂ post fertilization (dpf).</title><p>A <italic>ccm2<sup>-/-</sup></italic> embryo displayed heart dilation but no CVP dilation (<bold>A, Aâ, and Aâ</bold>) compared with a <italic>ccm2<sup>+/-</sup></italic> embryoÂ (B, <bold>Bâ,Â and Bâ</bold>). A <italic>ccm2</italic> morphant displayed heart dilation but no CVP dilation (<bold>C, C, and Câ</bold>) compared with a control morphant (<bold>D, D, and Dâ</bold>). Scale bar:Â 500 Âµm (<bold>A, B, C, and D</bold>), 200 Âµm (<bold>Aâ, Bâ, Câ, and Dâ</bold>), 50 Âµm (<bold>Aâ, Bâ, Câ, and Dâ</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig3-figsupp1-v3.tif"/></fig></fig-group><media id="video5" mime-subtype="mp4" mimetype="video" xlink:href="elife-62155-video5.mp4"><label>Video 5.</label><caption><title>Laser ablation of intussusception reduced the vessel diameter.</title></caption></media></sec><sec id="s2-4"><title>Blood flow and red blood cells are required for CVP dilation</title><p>The importance of the pillars in CVP dilation suggested that obstruction of blood flow was responsible for the phenotype. Consistently, as noted above, <italic>ccm2</italic> CRISPR embryos displaying CVP dilation did not show heart dilation. Conversely, segmental CVP dilation was absent in <italic>ccm2</italic> null mutants or <italic>ccm2</italic> morphants that exhibit characteristic heart dilation (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). These observations suggest that a normally pumping heart and thus normal blood flow is required for CVP dilation. To investigate the role of blood flow, we took advantage of the capacity of zebrafish embryos to obtain sufficient oxygen by diffusion to survive temporarily in the absence of circulating blood. We induced a silent heart phenotype by using a troponin T (<italic>tnnt</italic>) morpholino, resulting inÂ ~65% reduction in the frequency of CVP dilation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We also reasoned that the meshwork of pillars would not obstruct fluid flow but would present a barrier to free passage of erythrocytes. Reduction of erythrocytes using morpholinos directed against <italic>gata1</italic>(<xref ref-type="bibr" rid="bib12">Galloway et al., 2005</xref>) or <italic>tif1-Î³</italic> (<xref ref-type="bibr" rid="bib34">Monteiro et al., 2011</xref>) transcription factors produced a similar dramatic reduction in the CVP dilation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These data indicate that the meshwork of pillars obstructs the passage of erythrocytes in flowing blood resulting in multiple erythrocyte-filled cavernous chambers that dilate the CVP.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Blood flow is required for pillar formation and vessel dilation.</title><p>Morpholinos targeting <italic>tnnt</italic>, <italic>gata1</italic>, <italic>tif1gamma</italic>, or a control morpholino were co-injected with <italic>ccm2</italic> guide and Cas9 RNA. (<bold>A</bold>) Reduction of blood flow in <italic>tnnt</italic> morphants (<bold>A, B, C</bold>) resulted in reduced caudal venous plexusÂ (CVP) dilation (<bold>A</bold>) and intravascular honeycombing (<bold>B, C</bold>) in 2Â daysÂ post fertilization (dpf) <italic>ccm2</italic> CRISPR <italic>Tg(fli1:EGFP)</italic> embryos. Arrows indicate intussusceptions. Scale bar: 100 Âµm. (<bold>A</bold>) Loss of erythrocytes in <italic>gata1 or tif1gamma</italic> morphant <italic>ccm2</italic> CRISPR embryos also reduced the incidence of CVP dilation. p-Values were calculated using one-way ANOVA. **p&lt;0.01. Error bars indicate SD. (<bold>D and E</bold>) At 23Â hpf, <italic>ccm2</italic> CRISPR <italic>Tg(klf2a:H2b-EGFP)</italic> embryos displayed a mosaic increase of EGFP expression in endothelial cells in the CVP (<bold>D</bold>), compared with cas9 mRNA control embryos (<bold>E</bold>). Scale bar: 25 Âµm. (<bold>F</bold>) Quantification of the EGFP fluorescence intensity using ImageJ. A total of 20 nuclei were analyzed from <italic>ccm2</italic> CRISPR embryos, and 16 nuclei were analyzed from control embryos. Note that 11 nuclei in CRISPR embryo displayed intensity above 3000, while all of the nuclei in control embryo are below 3000. (<bold>G</bold>) <italic>ccm2</italic> CRISPR and <italic>tnnt</italic> morpholino-injected <italic>Tg(klf2a:H2b:EGFP</italic> 2Â dpf) embryos displayed a mosaic increase of endothelial nuclear EGFP expression in dorsal vein. Scale bar: 50 Âµm. In A through C, EGFP expression was driven by <italic>klf2a</italic> promoter in <italic>Tg(klf2a:H2b:EGFP)</italic> embryo, and endothelial cells were labeled by mcherry in <italic>Tg(kdrl:mcherry)</italic> transgenic line. Arrows indicated the endothelial nuclei with increased EGFP, and arrowheads indicated the other endothelial nuclei along the ventral wall of dorsal vein.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>Whole mount in situ hybridization showed mosaic upregulation of klf2a expression in <italic>ccm2</italic> CRISPR embryos (left) compared to that of control (right).</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 2.</label><caption><title>Klf2a expression is regulated by ccm2 expression and by blood flow.</title><p>(<bold>A and Aâ</bold>) A <italic>ccm2</italic> morphant displayed an increase of endothelial nuclear EGFP KLF2a reporter expression, whereas a <italic>tnnt</italic> morphant displayed a decrease of endothelial nuclear EGFP KLF2a reporter expression compared with a control morpholino-injected embryo (<bold>C and Câ</bold>). EGFP expression was driven by <italic>klf2a</italic> promoter in <italic>Tg(klf2a:H2b-EGFP)</italic>, and endothelial cells were labeled by mcherry in <italic>Tg(kdrl:mcherry)</italic>. Arrows indicated the endothelial cell nucleus. Scale bar: 50 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig4-figsupp2-v3.tif"/></fig></fig-group><p>As shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, the sprouts that form the ventral vein are lost in the dilated region of the CVP. Because CVP development in <italic>tnnt</italic> morphants is nearly normal (<xref ref-type="bibr" rid="bib6">Choi et al., 2011</xref>), we inspected the regions of the CVP displaying loss of ventral sprouting in <italic>tnnt</italic> morphant <italic>ccm2</italic> CRISPR embryos. In 11 such embryos, in spite of the defective ventral sprouting and ventral vein formation, we observed no intravascular pillars. This result suggests that blood flow, in addition to causing the CVP dilation, is required for intussusceptive pillar formation (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>) as it is for normal CVP arborizationÂ (<xref ref-type="bibr" rid="bib21">Karthik et al., 2018</xref>).</p><p>Inactivation of either <italic>ccm1</italic> or <italic>ccm2</italic> markedly upregulates expression of KLF2, a flow-regulated transcription factor required for normal cardiovascular development and for CCM formation (<xref ref-type="bibr" rid="bib41">Renz et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Zhou et al., 2015</xref>; <xref ref-type="bibr" rid="bib55">Zhou et al., 2016</xref>). In situ hybridization revealed that <italic>klf2a</italic> was also upregulated in the CVP of <italic>ccm2</italic> CRISPR embryos (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). We used a <italic>klf2a</italic> reporter line, <italic>Tg(klf2a:H2AEGFP)</italic>, together with an endothelial cell-specific marker line (<italic>Tg(kdrl:mcherry)<sup>is5</sup></italic>) to observe the activity of the <italic>klf2a</italic> promoter. <italic>Ccm2</italic> morphants displayed a generalized increase in <italic>klf2a</italic> reporter expression (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2A and Aâ</xref>), whereas the absence of blood flow in the <italic>tnnt</italic> morphant caused much reduced reporter expression in endothelial cells (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2B and Bâ</xref>;Â <xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2C and Câ</xref>). Consistent with previous reports (<xref ref-type="bibr" rid="bib39">Parmar, 2006</xref>; <xref ref-type="bibr" rid="bib41">Renz et al., 2015</xref>), these opposing changes confirm that <italic>ccm2</italic> and flow can regulate expression of KLF2a. In 23 hpf <italic>ccm2</italic> CRISPR embryos, examined prior to onset of blood flow, a patchy increase in <italic>klf2a</italic> reporter expression was observed in <italic>ccm2</italic> CRISPR endothelial cells (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), whereas reporter expression was uniformly low in control embryos at the same stage (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). A quantitative analysis revealed a subpopulation of high KLF2a-expressing endothelial cells in <italic>ccm2</italic> CRISPR embryos that was absent in control embryos (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Furthermore, in <italic>tnnt</italic> morphant 2Â dpf <italic>ccm</italic>2 CRISPR embryos, there was also a striking mosaic increase in endothelial <italic>klf2a</italic> reporter expression (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Thus, dilation was associated with the patchy upregulation of a flow-sensitive transcription factor, KLF2, in the <italic>ccm2</italic> CRISPR CVP. Taken together, these results suggest that patchy KLF2 expression in combination with blood flow leads to formation of these dilated RBC-filled multi-cavernous lesions in the CVP.</p></sec><sec id="s2-5"><title>Mosaic upregulation of KLF2a is sufficient for cavernoma formation in CVP</title><p>The patchy increase in KLF2a expression in the CVP endothelial cells of <italic>ccm2</italic> CRISPR embryos and requirement for blood flow suggested the possibility that these two factors led to the formation of cavernomas in the CVP. To address the role of KLF2, we injected <italic>klf2a</italic> and <italic>klf2b</italic> morpholinos and observed reversal of both CVP dilation and heart dilation in the <italic>ccm2</italic> CRISPR embryos (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Furthermore, <italic>ccm2</italic> CRISPR treatment of <italic>klf2a<sup>-/-</sup></italic> embryos caused no CVP dilation (<xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>). Thus, <italic>klf2a</italic> is required for the CVP dilation phenotype.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Mosaic KLF2a expression caused caudal venous plexusÂ (CVP) dilation.</title><p>(<bold>A</bold>) Both the CVP dilation and heart dilation were rescued by injection of <italic>klf2</italic> morpholinos in 2Â daysÂ post fertilization (dpf) <italic>ccm2</italic> CRISPR embryos. **p&lt;0.01. Error bars indicate SD. (<bold>B</bold>) <italic>pCS2-</italic>KLF2a linearized DNA-injected 2.5 dpf embryos displayed CVP dilation, whereas injection of a DNA fragment containing a DNA binding domain deleted ÎKLF2a mutant showed normal development. Arrow indicates the CVP dilation and retained erythrocytes. Scale bar: 1 mm. (<bold>C</bold>) Quantification of the prevalence of CVP dilation following KLF2a or ÎKLF2a overexpression. The mean and SD are shown. (<bold>D</bold>) Representative images show the honeycombed lumen and dilated CVP in 1.5Â dpf KLF2a-injected embryo and normal CVP of ÎKLF2a-injected embryo. Arrow indicates honeycombing. Scale bar: 100 Âµm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 1.</label><caption><title>Reduced caudal venous plexusÂ (CVP) dilation in <italic>ccm2</italic> CRISPR <italic>klf2a<sup>-/-</sup></italic> embryos.</title><p>Total number of embryos in each group is indicated on the graph. ***p&lt;0.0001. Two-tailed Fisherâs exact test was used for comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig5-figsupp1-v3.tif"/></fig></fig-group><p>In <italic>ccm2</italic> CRISPR embryos, KLF2a was both upregulated in a mosaic fashion and required for CVP dilation; we therefore asked whether mosaic upregulation of KLF2a expression per se causes cavernoma formation. Mosaic overexpression was accomplished by injecting a plasmid encoding KLF2a <italic>into Tg(fli1:EGFP</italic>)<italic><sup>y1</sup></italic> embryos;Â ~6% of such embryos displayed CVP dilation compared to control embryos injected with ÎKLF2a plasmid expressing KLF2a with a deleted DNA binding domain (<xref ref-type="bibr" rid="bib36">Oates et al., 2001</xref>;Â <xref ref-type="fig" rid="fig5">Figure 5B and C</xref>). Affected embryos exhibited intussusceptions within the CVP lumen accompanied by dilation (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). These observations show that mosaic upregulation of KLF2a expression is sufficient for cavernoma formation when blood is flowing.</p></sec><sec id="s2-6"><title>Mosaic expression of ccm2 causes KLF2a-dependent cavernoma formation</title><p><italic>ccm2</italic> CRISPR caused mosaic inactivation of <italic>ccm2</italic> and the dilated CVP phenotype, whereas global inactivation of <italic>ccm2</italic> in <italic>ccm2</italic> null mutants or <italic>ccm2</italic> morphants does not. We therefore questioned whether mosaicism, per se, played a role in the CVP dilation. To test this idea, we globally reduced <italic>ccm2</italic> expression by co-injecting a sublethal dose of <italic>ccm2</italic> morpholino with the <italic>ccm2</italic> gRNA CRISPR mixture. The chosen morpholino dose did not increase the frequency of observable heart defects; however, the percentage of embryos displaying CVP dilation decreased dramatically (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We then reasoned that because <italic>ccm2</italic> acts as a scaffold connecting <italic>krit1</italic> to <italic>ccm3</italic> (<xref ref-type="bibr" rid="bib44">Stahl et al., 2008</xref>), the overexpression of <italic>ccm2</italic> might have a dominant negative effect. Indeed, when we injected linearized DNA containing <italic>ccm2</italic> fused to m-Orange, <italic>ccm2</italic> mosaic overexpression led to CVP dilation and aberrant intussusceptions similar to those observed in <italic>ccm2</italic> CRISPR embryos inÂ ~8% of embryos (<xref ref-type="fig" rid="fig6">Figure 6B and Bâ</xref>). In sharp contrast, injection of a plasmid encoding a loss of krit1 binding function <italic>ccm2(L197R)</italic> mutant (<xref ref-type="bibr" rid="bib22">Kleaveland et al., 2009</xref>) resulted in of embryos displaying a normal vascular development (<xref ref-type="fig" rid="fig6">Figure 6C and Câ</xref>). Importantly, mosaic overexpression of <italic>ccm2</italic> caused significantly less CVP dilation in <italic>klf2a<sup>-/-</sup></italic> embryos (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1</xref>). Thus, mosaicism for <italic>ccm2</italic> expression causes <italic>klf2a</italic>-dependent formation of multi-cavernous erythrocyte-filled structures in the CVP. Combined with the capacity of mosaic expression of <italic>klf2a</italic> to cause CVP dilation, these results show that mosaic expression of CCM2 leads to mosaic KLF2a expression and abortive intussusceptive angiogenesis that obstructs the lumen to form these cavernoma-like lesions.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Mosaic <italic>ccm2</italic> expression caused caudal venous plexusÂ (CVP) dilation.</title><p>(<bold>A</bold>) Low-dose <italic>ccm2</italic> morpholino reduced the incidence of CVP dilation but did not significantly increase heart dilation in <italic>ccm2</italic> CRISPR embryos. (<bold>B and C</bold>) Mosaic <italic>ccm2</italic> but not inactive <italic>ccm2(L197E)</italic> overexpression caused CVP dilation. Arrows indicate pillars in the CVP. (<bold>Bâ and Câ</bold>) Mosaic expression of mOrange-tagged <italic>ccm2</italic> or <italic>ccm2(L197E)</italic>. Scale bar: 100 Âµm. Error bars areÂ Â±Â SD.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>Reduced caudal venous plexusÂ (CVP) dilation in CCM2 over expressing <italic>klf2a<sup>-/-</sup></italic> embryos.</title><p>The 200 ng/Î¼l linearized DNA fragment containing CMV promoter, <italic>ccm2</italic> coding sequence, and SV40 was injected into one-cell stage embryos. Total number of embryos in each group is indicated on the graph. The <italic>klf2a<sup>-/-</sup></italic>embryos exhibited a significant (p=0.0218) reduction in CVP dilation. Two-tailed Fisherâs exact test was used for comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig6-figsupp1-v3.tif"/></fig></fig-group></sec><sec id="s2-7"><title>CCMs in adult zebrafish</title><p>The foregoing data indicated that mosaic inactivation of <italic>ccm2</italic> results in a multi-cavernous lesion in the embryonic CVP that resembles mammalian CCM in gross architecture and dependence on KLF2. We then asked if authentic CCM would develop in theÂ ~50% of <italic>ccm2</italic> CRISPR embryos that developed with a normal gross morphology and survived to adulthood. Brain vascular lesions were observed in virtually all of these adult <italic>ccm2</italic> CRISPR zebrafish (<xref ref-type="fig" rid="fig7">Figure 7A and C</xref>) and not in control fish (<xref ref-type="fig" rid="fig7">Figure 7E and G</xref>). In order to image the lesions at the whole brain level, clear, unobstructed brain imaging cocktails and computational analysis (CUBIC) was applied to these brains, and the transparent brains were scanned by light sheet microscopy (<xref ref-type="fig" rid="fig7">Figure 7B,D,F and H</xref>). The distribution of lesions included cerebrum, cerebellum, brain stem, and, in some fish, the spinal cord (<xref ref-type="fig" rid="fig7">Figure 7I</xref>). This distribution pattern is similar to that found in patientsÂ (<xref ref-type="bibr" rid="bib14">Goldstein and Solomon, 2017</xref>). Hematoxylin and eosin stained sections showed dilated multi-cavernous vascular channels filled with nucleated erythrocytes and lacking mature vessel wall angioarchitecture (<xref ref-type="fig" rid="fig7">Figure 7J</xref>). Perlâs Prussian blue staining indicated prior hemorrhage adjacent to the lesions (<xref ref-type="fig" rid="fig7">Figure 7K</xref>). These histological findings were absent in control fish (<xref ref-type="fig" rid="fig7">Figure 7L and M</xref>) and resemble those in CCM patients (<xref ref-type="fig" rid="fig7">Figure 7N and O</xref>;Â <xref ref-type="bibr" rid="bib7">Cox et al., 2017</xref>). A dramatic reduction in CCM was seen in <italic>ccm2</italic> CRISPR in <italic>klf2a<sup>-/-</sup></italic> zebrafish (<xref ref-type="bibr" rid="bib46">Steed et al., 2016</xref>;Â <xref ref-type="fig" rid="fig7">Figure 7P</xref>) consistent with previous murine studies in which inactivation of <italic>Klf2</italic> prevented CCM formationÂ (<xref ref-type="bibr" rid="bib55">Zhou et al., 2016</xref>). In addition, similar to humans, these adult zebrafish also developed extracranial lesions (<xref ref-type="fig" rid="fig7s1">Figure 7âfigure supplement 1</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Adult <italic>ccm2</italic> CRISPR zebrafish develop typical cerebral cavernous malformationÂ (CCM) lesions.</title><p>TheÂ ~50%Â of <italic>ccm2</italic> CRISPR fish that survived developed highly penetrant CCMs (<bold>A and C</bold>). Arrows indicate superficial lesions on dorsal (<bold>A</bold>) and ventral (<bold>C</bold>) surface of the brain. Note hemorrhage into the ventricles. Lesions are absent in control embryos (<bold>E and G</bold>). Clear, unobstructed brain imaging cocktails and computational analysis (CUBIC) clearing (<bold>B, D, F, H</bold>) enables visualization of CCM burden by light sheet microscopy. Arrows indicate the lesions that corresponded to those seen in bright field, and arrowhead indicates a deeper lesion. L: left, R: right. Scale bar: 1 mm. (<bold>I</bold>) Cavernomas were dispersed throughout the central nervous system including cerebrum, cerebellum, brain stem, and spinal cord. (<bold>J</bold>) Hematoxylin and eosin (H&amp;E) stained brain section reveals nucleated erythrocytes filling a dilated vessel with adjacent Prussian blue stained iron deposition (<bold>K</bold>) in <italic>ccm2</italic> CRISPR fish and the absence of lesions or iron deposition in control fish (<bold>L,Â M</bold>). (<bold>N,Â O</bold>) A CCM from a patient stained with H&amp;E (<bold>N</bold>) or Prussian blue (<bold>O</bold>). Note similar appearance to the zebrafish lesion shown in (<bold>J,Â K</bold>). Arrow indicates dilated vessel. Scale bar: 50 Âµm. (<bold>P</bold>) CCMs were significantly reduced in <italic>ccm2</italic> CRISPR adult fish on <italic>klf2a<sup>-/-</sup></italic> background compared to that on <italic>klf2a<sup>+/+</sup></italic> background. Total number of embryos in each group is indicated. p=0.0076. Two-tailed Fisherâs exact test was used for comparison.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig7-v3.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7âfigure supplement 1.</label><caption><title><italic>Ccm2</italic> CRISPR adult fish displayed body wall lesions.</title><p>Casper fish embryos were injected with <italic>ccm2</italic> CRISPR and raised to 2.5 months. Arrows indicated the dilated vessels in the body wall. Scale bar: 1 cm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig7-figsupp1-v3.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7âfigure supplement 2.</label><caption><title>Inhibiting Rho kinase blocks caudal venous plexusÂ (CVP) cavernoma formation in <italic>ccm2</italic> CRISPR zebrafish.</title><p>At 24Â hpf, <italic>ccm2</italic> CRISPR embryos were treated with 45 Î¼M Y-27632(Tocris) in egg water as described by Uehata et al. (<bold>Nature:</bold> <italic>389</italic> (1997) pp. 990â994) and controls were treated with 1% DMSO. At 2Â daysÂ post fertilization (dpf), in contrast to DMSO-treated embryos, no embryos treated with Y-27632 exhibited CVP dilation (**p=0.0098) or other obvious developmental anomalies. Total number of embryos in each group is indicated above the bars. Two-tailed Fisherâs exact test was used for comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-62155-fig7-figsupp2-v3.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Familial CCM lesions form as a consequence of mosaic complete inactivation of <italic>CCM1, -2,</italic> or -<italic>3.</italic> Here, we have used Cas9-CRISPR mutagenesis to create such a mosaicism for <italic>ccm2</italic> in zebrafish and show that surviving adult <italic>ccm2</italic> CRISPR animals develop brain and extracranial lesions that closely resemble those observed in humans with CCM. InÂ ~30% of embryos, we observed a novel phenotype, the formation of segmental dilatation of the caudal vein associated with slowed blood flow and formation of multiple markedly dilated blood-filled chambers, resembling a multi-cavernous CCM. These lesions are caused by intussusceptive intraluminal pillars that obstruct the passage or erythrocytes resulting in the development of multiple dilated blood-filled chambers. These pillars form as a consequence of a combination of blood flow and mosaic overexpression of a flow-dependent transcription factor, KLF2a, leading to aberrant flow sensing in the developing CVP. In sum, our studies describe a zebrafish model for CCM and provide a new mechanism that can explain the formation of the characteristic multi-cavernous lesions seen in humans.</p><sec id="s3-1"><title>The role of blood flow in CVP dilation</title><p>The segmental dilation of the CVP is due to intussusceptive pillars that fail to fuse normally, thus honeycombing the vein lumen and obstructing the free flow of erythrocytes. Evidence for the role of obstruction includes the marked slowing of blood flow within the lesions, dependence of dilation on blood flow and erythrocytes, and the relief of dilation by spontaneous or induced regression of the pillars. Intussusceptive angiogenesis differs from sprouting angiogenesis by splitting the existing vessel intraluminally as a response to increased blood flow (<xref ref-type="bibr" rid="bib10">Djonov et al., 2003</xref>; <xref ref-type="bibr" rid="bib11">Egginton et al., 2001</xref>). Recent elegant studies have shown that localized reduction in fluid shear stress occurs adjacent to intussusceptive pillars and is associated with the formation of new pillars that align with existing pillars (<xref ref-type="bibr" rid="bib21">Karthik et al., 2018</xref>). These observations suggested that these blood flow patterns are responsible for the formation of the aligned pillars required for orderly fusion to split the vessel in twoÂ (<xref ref-type="bibr" rid="bib21">Karthik et al., 2018</xref>). Similar to physiological intussusceptive angiogenesis, the hallmark pits and intraluminal pillars were also observed in the CVP of <italic>ccm2</italic> CRISPR embryos; however, these pillars failed to undergo orderly fusion to split the vessel. We propose that this failure to undergo orderly fusion and CVP arborization is due to mosaic overexpression of <italic>klf2a</italic>, a flow-sensitive transcription factor, thus disrupting the required orderly flow signaling (<xref ref-type="bibr" rid="bib21">Karthik et al., 2018</xref>). The meshwork formed by these intraluminal endothelial pillars partitions the patent lumen into multiple blood-filled chambers (<xref ref-type="fig" rid="fig3">Figure 3I and J</xref>, <xref ref-type="video" rid="video2">Videos 2</xref> and <xref ref-type="video" rid="video3">3</xref>). As more and more RBCs accumulate, the CVP becomes dilated (<xref ref-type="video" rid="video1">Video 1</xref>).</p><p>In contrast to the necessity of blood flow for formation of the multi-cavernous CVP lesions, in <italic>ccm2</italic> CRISPR zebrafish, blood flow suppresses endothelial proliferation and simple vessel dilation in <italic>krit1</italic> global null zebrafish (<xref ref-type="bibr" rid="bib42">RÃ¶del et al., 2019</xref>). As shown here, vessels mosaic for expression of a CCM gene require blood flow to form the intravascular pillars that obstruct blood flow and cause multi-cavernous lesions. Previous studies termed dilated capillaries Stage 1 CCM and multi-cavernous lesions Stage 2 CCM (<xref ref-type="bibr" rid="bib52">Zeineddine et al., 2019</xref>). The differential flow requirements for formation of dilated vessels and multi-cavernous lesions in zebrafish suggest that the Stage 1 and Stage 2 forms of CCM can employ distinct pathogenetic mechanisms.</p></sec><sec id="s3-2"><title><italic>Ccm2</italic> mosaicism causes multi-cavernous malformations</title><p>Initially we ascribed the absence of segmental CVP dilation in <italic>ccm2</italic> null fish (<xref ref-type="bibr" rid="bib29">Mably et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Renz et al., 2015</xref>) solely to the reduced blood flow caused by the dilated heart. This explanation is insufficient because rescue of the heart phenotype in global <italic>krit1 (ccm1)</italic> null fish was not reported to cause segmental CVP dilation or CCMs (<xref ref-type="bibr" rid="bib42">RÃ¶del et al., 2019</xref>). Normal intussusceptive angiogenesis requires an orderly patterning of high and low flow signalingÂ (<xref ref-type="bibr" rid="bib21">Karthik et al., 2018</xref>). <italic>Ccm2</italic> mosaicism causes a random upregulation of <italic>klf2a</italic>, a key effector of flow signaling, thereby disrupting this orderly patterning of flow signaling. In contrast, the global knockout uniformly upregulates klf2a so that the patterning of other flow-sensitive signals can guide the completion of the intussusceptive arborization.</p><p>The dilated multi-cavernous CVP lesions described here resemble multi-cavernous CCM (<xref ref-type="bibr" rid="bib31">McDonald et al., 2011</xref>) and their formation required mosaicism. Recent studies found that multi-cavernous murine CCMs are mosaic for inactivation of <italic>Ccm3</italic> (<xref ref-type="bibr" rid="bib9">Detter et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Malinverno et al., 2019</xref>). The mouse studies emphasized that simply dilated vessels are not mosaic and contained only <italic>Ccm3</italic> null endothelial cells (<xref ref-type="bibr" rid="bib9">Detter et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Malinverno et al., 2019</xref>). Mosaicism in multi-cavernous murine CCM was ascribed to recruitment of wild-type cells to the clonal CCMÂ (<xref ref-type="bibr" rid="bib9">Detter et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Malinverno et al., 2019</xref>). Importantly, the mouse studies did not address the mechanism by which multi-cavernous lesions form. Here, we have shown that mosaicism is a prerequisite for formation of multi-cavernous CVP lesions because it disorganizes the flow signaling required for orderly sprouting and intussusceptive angiogenesis that remodel the CVP.</p></sec><sec id="s3-3"><title><italic>Ccm2</italic> CRISPR zebrafish are an authentic CCM model</title><p>As in humans (<xref ref-type="bibr" rid="bib2">Akers et al., 2009</xref>; <xref ref-type="bibr" rid="bib31">McDonald et al., 2011</xref>), the fish CCM lesions arise as a consequence of mosaic inactivation of CCM genes. Second, as in humans, chronic bleeding leads to iron deposition; this finding contrasts with the lack of iron deposition seen in acute mouse CCM models (<xref ref-type="bibr" rid="bib52">Zeineddine et al., 2019</xref>). Third, similar to humans, histologically typical lesions are distributed throughout the CNS in contrast to the hindbrain-restricted lesions in acute mouse modelsÂ (<xref ref-type="bibr" rid="bib52">Zeineddine et al., 2019</xref>). Fourth, as is true in mouse models (<xref ref-type="bibr" rid="bib8">Cuttano et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Zheng et al., 2014</xref>), the development of CCM depends on <italic>klf2a</italic>, the orthologue of murine <italic>Klf2</italic> and paralogue of <italic>Klf4</italic>, indicating that they form by the same pathogenetic mechanism. That said, in contrast to the KLF2Â dependence of CVP dilation, injection of a KLF4 morpholino (<xref ref-type="bibr" rid="bib26">Li et al., 2011</xref>) did not rescue this lesion (our unpublished data). There are chronic sensitized mouse models which do exhibit hemosiderin deposits and lesions throughout the CNS (<xref ref-type="bibr" rid="bib31">McDonald et al., 2011</xref>); however, these models require cumbersome breeding schemes and mice of more than 3 months of age. That said, a recent report that postnatal induction of brainÂ endothelialÂ cell-specific ablation of the <italic>Ccm2</italic> gene using the inducible <italic>Slco1c1</italic>-CreER<sup>T2</sup> mouse results in iron deposits around CCM throughout the murine brain at 3 months of age has great promise (<xref ref-type="bibr" rid="bib4">Cardoso et al., 2020</xref>). In contrast to existing mouse models, the present model uses CRISPR-Cas9 to generate highly penetrant typical lesions throughout the CNS, requires about 2 months, and can be induced in mutant strains without additional breeding. Thus, this model should be aÂ useful tool in future studies to assess the effect of the many genetic manipulations possible in zebrafish (<xref ref-type="bibr" rid="bib15">Gore et al., 2018</xref>) on the pathogenesis of CCM and to provide a complement to pharmacological screens directed at the dilated heart phenotype of <italic>ccm1</italic> or <italic>ccm2</italic> mutant fish (<xref ref-type="bibr" rid="bib38">Otten et al., 2018</xref>).</p><p>In sum, the present work reveals a new embryonic vascular malformation, a multi-cavernous dilation of the CVP that resembles multi-cavernous Stage 2 CCM. The CVP malformation requires blood flow and mosaic inactivation of <italic>ccm2</italic> and is caused by abortive intussusceptive angiogenesis as a consequence of imbalanced flow signaling. The high penetrance and resemblance of the embryonic CVP malformation to multi-cavernous CCM suggest that it will be a useful phenotype for pharmacological or morpholino-based analyses. That said, the CVP does lack CNS accessory cells, such as astrocytesÂ (<xref ref-type="bibr" rid="bib28">Lopez-Ramirez et al., 2021</xref>), that promote CCM development. Indeed, we recently reported that propranolol blocks the embryonic CVP malformation by Î²1 adrenergic receptor antagonismÂ (<xref ref-type="bibr" rid="bib27">Li et al., 2021</xref>), a result that comports with the beneficial effects of propranolol in murine CCM modelsÂ (<xref ref-type="bibr" rid="bib27">Li et al., 2021</xref>; <xref ref-type="bibr" rid="bib37">Oldenburg et al., 2021</xref>) and in anecdotal reports in humansÂ (<xref ref-type="bibr" rid="bib23">Lanfranconi et al., 2020</xref>; <xref ref-type="bibr" rid="bib40">Reinhard et al., 2016</xref>). We have found that blockade or Rho kinase also ameliorates the CVP lesion (<xref ref-type="fig" rid="fig7s2">Figure 7âfigure supplement 2</xref>) as it does murine CCMÂ (<xref ref-type="bibr" rid="bib32">McDonald et al., 2012</xref>). In addition, we report a tractable zebrafish model of CNS CCM that mimics the mammalian disease in mosaicism, lesion histology and distribution, and dependence on KLF2 transcription factors. A particularly appealing feature of these two new zebrafish models is that disease pathogenesis can be studied on mutant backgrounds without the need for additional breeding. Manipulations that ameliorate the embryonic lesion can then readily be tested for effects on the formation of brain CCMs that occur in the 50% of <italic>ccm2</italic> CRISPR embryos that survive to adulthood.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Gene (<italic>Danio rerio</italic>)</td><td valign="top">ccm2</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/">http://www.ensembl.org/</ext-link></td><td valign="top">ENSDARG00000013705</td><td valign="top"/></tr><tr><td valign="top">Gene (<italic>Danio rerio</italic>)</td><td valign="top">klf2a</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org/">http://www.ensembl.org/</ext-link></td><td valign="top">ENSDARG00000042667</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">ccm2<sup>m201</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-980203â523</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">klf2a<sup>ig4</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-161103â5</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">Tg(fli1:EGFP)<sup>y1</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-011017â8</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">Tg(gata1:dsred)<sup>sd2</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-051223â6</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">Tg(klf2a:H2b-EGFP)</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-161017â10</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">Tg(fli1:negfp)<sup>y7</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-060821â4</td><td valign="top"/></tr><tr><td valign="top">Strain, strain background (<italic>Danio rerio</italic>)</td><td valign="top">Tg(kdrl:mcherry)<sup>is5</sup></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-ALT-110127â25</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pCS2-nls-zCas9-nls</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.addgene.org/">addgene.org</ext-link></td><td valign="top">47929</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/46759/">pT7-gRNA</ext-link></td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.addgene.org/">addgene.org</ext-link></td><td valign="top">46759</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">mMESSAGE mMACHINE SP6 Transcription Kit</td><td valign="top">ThermoÂ Fisher Scientific <break/>Wlatham,Â MA</td><td valign="top">AM1340</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">MEGAshortscript T7 Transcription kit</td><td valign="top">ThermoÂ Fisher Scientific,Â Waltham,Â MA</td><td valign="top">AM1333</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">crRNA-1</td><td valign="top">This paper</td><td valign="top">ccm2 gRNA</td><td valign="top"><named-content content-type="sequence">GGTGTTTCTGAAAGGGGAGA</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">crRNA-2</td><td valign="top">This paper</td><td valign="top">ccm2 gRNA</td><td valign="top"><named-content content-type="sequence">GGAGAAGGGTAGGGATAAGA</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">crRNA-3</td><td valign="top">This paper</td><td valign="top">ccm2 gRNA</td><td valign="top"><named-content content-type="sequence">GGGTAGGGATAAGAAGGCTC</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">crRNA-4</td><td valign="top">This paper</td><td valign="top">ccm2 gRNA</td><td valign="top"><named-content content-type="sequence">GGACAGCTGACCTCAGTTCC</named-content></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">ccm2-MO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-MRPHLNO-060821â3</td><td valign="top"><named-content content-type="sequence">GAAGCTGAGTAATACCTTAACTTCC</named-content></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">tnnt-MO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-MRPHLNO-060317â4</td><td valign="top"><named-content content-type="sequence">CATGTTTGCTCTGATCTGACACGCA</named-content></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">gata1-MO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-MRPHLNO-050208â10</td><td valign="top"><named-content content-type="sequence">CTGCAAGTGTAGTATTGAAGATGTC</named-content></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">tif1Î³ -MO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://afin.org/">afin.org</ext-link></td><td valign="top">ZDB-MRPHLNO-110321â1</td><td valign="top"><named-content content-type="sequence">GCTCTCCGTACAATCTTGGCCTTTG</named-content></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">klf2a-MO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://afin.org/">afin.org</ext-link></td><td valign="top">ZDB-MRPHLNO-100610â8</td><td valign="top"><named-content content-type="sequence">GGACCTGTCCAGTTCATCCTTCCAC</named-content></td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">klf2b-MO</td><td valign="top"><ext-link ext-link-type="uri" xlink:href="http://zfin.org/">zfin.org</ext-link></td><td valign="top">ZDB-MRPHLNO-150427â1</td><td valign="top"><named-content content-type="sequence">AAAGGCAAGGTAAAGCCATGTCCAC</named-content></td></tr><tr><td valign="top">Software</td><td valign="top">Volocity</td><td valign="top">PerkinElmer <break/>Waltham,Â MA</td><td valign="top">Volocity</td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">ZEN</td><td valign="top">Zeiss,Â Oberkochen, German</td><td valign="top">ZEN 2.3 SP1</td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">ImageJ software</td><td valign="top">ImageJ (<ext-link ext-link-type="uri" xlink:href="http://imagej.nih.gov/ij/">http://imagej.nih.gov/ij/</ext-link>)</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">GraphPad Prism software</td><td valign="top">GraphPad Prism (<ext-link ext-link-type="uri" xlink:href="https://graphpad.com">https://graphpad.com</ext-link>)</td><td valign="top">Prism five for Windows</td><td valign="top">Version 5.01</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Zebrafish lines and husbandry</title><p>Zebrafish were maintained and with approval of Institutional Animal Care and Use Committee of the University of California, San Diego. The following mutant and transgenic lines were maintained under standard conditions: <italic>ccm2<sup>m201</sup></italic> (<xref ref-type="bibr" rid="bib29">Mably et al., 2006</xref>), <italic>klf2a<sup>ig4</sup></italic> (<xref ref-type="bibr" rid="bib46">Steed et al., 2016</xref>), <italic>Tg(fli1:EGFP)<sup>y1</sup></italic> (<xref ref-type="bibr" rid="bib24">Lawson and Weinstein, 2002</xref>), <italic>Tg(gata1:dsred)<sup>sd2</sup></italic> (<xref ref-type="bibr" rid="bib49">Traver et al., 2003</xref>), <italic>Tg(fli1:negfp)<sup>y7</sup></italic> (<xref ref-type="bibr" rid="bib43">Roman et al., 2002</xref>), <italic>Tg(klf2a:H2b-EGFP)</italic> (<xref ref-type="bibr" rid="bib17">Heckel et al., 2015</xref>), <italic>Tg(kdrl:mcherry)<sup>is5</sup></italic> (<xref ref-type="bibr" rid="bib20">Jin et al., 2005</xref>), and <italic>casper</italic> (<xref ref-type="bibr" rid="bib50">White et al., 2008</xref>). See Expanded Materials and Methods for morpholino injections. Morpholinos sequences are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> (Morpholino sequences).</p><p>Plasmids pCS2-nls-zCas9-nls (47929) and <ext-link ext-link-type="uri" xlink:href="https://www.addgene.org/46759/">pT7-gRNA</ext-link> (46759) were bought from Addgene. Crispr RNA (crRNA) sequences were listed in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> (crRNA sequences for zebrafish <italic>ccm2</italic>). Target gRNA constructs were generated as described before (<xref ref-type="bibr" rid="bib18">Jao et al., 2013</xref>). PCS2-morangeccm2, pCS2-morangeccm2 mutant(L197R), pCS2-morangeklf2a, pCS2-morangeÎklf2a were cloned by infusion (Clontech) as follows: mOrange was cloned into ClaI, and linker sequence (5â-<named-content content-type="sequence">ggcagcgcgggcagcgcggcgggcagcggcgaattt</named-content>-3â) between ClaI and EcoRI. Then ccm2, L197R mutant, klf2a or Îklf2a sequence were cloned into EcoRI, respectively. These plasmids were then double-digested by SalI and NotI (NEB), and the fragment containing CMV promoter and coding sequence were purified and 0.5 nl of a 200 ng/Î¼l solution was injected into single cell embryos. Primer sequences are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> (Primers for template DNA synthesis).</p></sec><sec id="s4-2"><title>RNA synthesis</title><p>For cas9 mRNA, pCS2-nls-zCas9-nls was digested by NotI and then purified by column (Macherey-Nagel) as template. Capped nls-zCas9-nls RNA was synthesized using mMESSAGE mMACHINE SP6 Transcription Kit (ThermoÂ Fisher Scientific) and purified through lithium chloride precipitation described in the same kit. For gRNA synthesis, gRNA constructs were linearized by BamHI digestion and purified by column (Macherey-Nagel). gRNA was synthesized by in vitro transcription using MEGAshortscript T7 Transcription kit (ThermoÂ Fisher Scientific) and purified by alcohol precipitation described in the same kit. The concentration of nls-zCas9-nls RNA and gRNA were measured by NanoDrop 1000 Spectrophotometer (ThermoÂ Fisher Scientific), and their quality was confirmed by electrophoresis through a 1% (wt/vol) agarose gel. The final concentrations for RNA injection are as follows: cas9 750 ng/Î¼l, gRNA 120 ng/Î¼l, and injection volume is 0.5 nl.</p></sec><sec id="s4-3"><title>Whole mount in situ hybridization</title><p>Zebrafish embryos were collected at 48Â hpf and fixed with 4% paraformaldehyde overnight. In situ hybridization was performed as described before (<xref ref-type="bibr" rid="bib48">Thisse and Thisse, 2008</xref>). The hybridization temperature is 68Â°C, and the probe concentration is 1 ng/Î¼l. For primers used to amplify the template DNA for probe synthesis, see Expanded Materials and Methods. The images for in situ hybridization were captured by Olympus MVX10, Macro-view.</p></sec><sec id="s4-4"><title>Airyscan imaging and 3D reconstruction</title><p>Embryos for imaging were anesthetized with egg water containing 0.016% tricaine (3-amino benzoic acid ethyl ester, Sigma-Aldrich) and then embedded in 1% low melting point agarose (Invitrogen 16520050). Imaging was performed with Zeiss 880 Airyscan confocal under the standard Airyscan mode, and a 20Ã/NA 0.8 objective was used. Maximum projection was performed with ZEN (Zeiss). 3D reconstruction was performed with Volocity (PerkinElmer).</p></sec><sec id="s4-5"><title>Laser ablation of intravascular pillars</title><p>Laser ablation of intravascular pillars was performed using targeted ultrafast laser pulses that were generated with a multi-pass Ti:Al<sub>2</sub>O<sub>3</sub> amplifier of local construction that followed a previously published design (<xref ref-type="bibr" rid="bib35">Nishimura et al., 2006</xref>) and operated at a 5 kHz pulseÂ rate. The ablation beam and the imaging beam were combined with a polarizing beamsplitter (<xref ref-type="bibr" rid="bib35">Nishimura et al., 2006</xref>) prior to the microscope objective. The two beams were focused in the same focal plane and the ablation beam was centered in the area that is raster-scanned by the imaging beam so that ablation occurred at the center of the TPLSM imaging field. The energy per pulse of the ablation beam was tuned with neutral density filters and the quantity of pulses was controlled by a mechanical shutter (Uniblitz LS3Z2 shutter and VMM-D1 driver; Vincent). The energy and number of pulses was adjusted based on damage evaluated from the real-time TPLSM images and ranged between 0.2Â andÂ 0.4Â Î¼J.</p></sec><sec id="s4-6"><title>Live imaging of endothelial pillar ablation</title><p>Live images of the fish vessels were obtained with a two-photon laser scanning microscope of local design (<xref ref-type="bibr" rid="bib35">Nishimura et al., 2006</xref>), which was adapted to include an ablation beam. Low-energy, 100Â fs, 76Â MHz pulses for TPLSM were generated by a Titanium:Sapphire laser oscillator (Mira F-900; Coherent Inc) that was pumped by a continuous wave laser (Verdi V-10 Nd:YVO4 laser; Coherent Inc). The imaging laser pulses were scanned in a raster pattern by galvanometric mirrors that are relay-imaged to the rear aperture of the objective. The two-photonÂ excited fluorescence is reflected by a dichroic mirror and transmitted to a photomultiplier tube. To produce laser pulses for ablation while imaging, we employed a Pockels cell (QS-3 with NVP-525D driver and DD1 timing circuit; Quantum Technologies) to reroute 1 in 76,000 pulses from the oscillator pulse train to seed a multipass Titanium:Sapphire amplifier that is pumped by a Q-switched laser (Corona; Coherent). A half-wave plate (Î»/2) rotates the polarization of the amplified pulses to lie perpendicular to that of the laser oscillator and thus permits both the ablation beam and the imaging beam to be routed to the microscope objective with a polarizing beamsplitter. We used a 25Ã/NA 0.95, waterÂ immersion objective (Olympus) for imaging and ablation.</p></sec><sec id="s4-7"><title>Histology</title><p>Hematoxylin and eosin stain and Perlâs Prussian blue stain were performed as describedÂ (<xref ref-type="bibr" rid="bib52">Zeineddine et al., 2019</xref>).</p></sec><sec id="s4-8"><title>Zebrafish brain dissection, CUBIC treatment, and light sheet imaging</title><p>Zebrafish brain dissection was performed as previously described (<xref ref-type="bibr" rid="bib16">Gupta and Mullins, 2010</xref>). CUBIC was optimized on the basis of previous report (<xref ref-type="bibr" rid="bib47">Susaki et al., 2015</xref>). The brains were fixed with pHÂ 7.5 4% PFA for 24 hr and then washed with PBS for 24 hr. After PBS wash, CUBICR1 treatment was then performed at 37Â°C in water bath for 42 hr. Samples were imaged in CUBICR2 as medium with ZEISS Lightsheet Z.1. Scanning was performed with 5Ã dual illumination optics and 5Ã objective.</p></sec><sec id="s4-9"><title>Statistical analysis</title><p>Statistical analysis was performed with GraphPad Prism. p-Values were calculated by paired two-tailed Studentâs t-test unless otherwise specifically indicated. The mean and SD were shown in the bar graphs.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We gratefully acknowledge Brant Weinstein for sharing a CUBIC protocol, David Traver, Miguel Lopez-Ramirez, Alexandre Gingras, and Sara McCurdy for valuable discussion and criticism, andÂ Jennifer Santini and Marcy Erb for microscopy technical assistance. We also acknowledge resources provided by the UCSD School of Medicine Microscopy Core (NINDS P30 NS047101).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#S14135 ) of the University of California San Diego.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Morpholino sequences.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62155-supp1-v3.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>crRNA sequence for zebrafish ccm2.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62155-supp2-v3.docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Primers for template DNA synthesis.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-62155-supp3-v3.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-62155-transrepform-v3.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Raw phenotype counts have been provided in figures and figure legends.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablain</surname> <given-names>J</given-names></name><name><surname>Durand</surname> <given-names>EM</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>Y</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish</article-title><source>Developmental Cell</source><volume>32</volume><fpage>756</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.01.032</pub-id><pub-id pub-id-type="pmid">25752963</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akers</surname> <given-names>AL</given-names></name><name><surname>Johnson</surname> <given-names>E</given-names></name><name><surname>Steinberg</surname> <given-names>GK</given-names></name><name><surname>Zabramski</surname> <given-names>JM</given-names></name><name><surname>Marchuk</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesis</article-title><source>Human Molecular Genetics</source><volume>18</volume><fpage>919</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn430</pub-id><pub-id pub-id-type="pmid">19088123</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulday</surname> <given-names>G</given-names></name><name><surname>Rudini</surname> <given-names>N</given-names></name><name><surname>Maddaluno</surname> <given-names>L</given-names></name><name><surname>BlÃ©con</surname> <given-names>A</given-names></name><name><surname>Arnould</surname> <given-names>M</given-names></name><name><surname>Gaudric</surname> <given-names>A</given-names></name><name><surname>Chapon</surname> <given-names>F</given-names></name><name><surname>Adams</surname> <given-names>RH</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name><name><surname>Tournier-Lasserve</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Developmental timing of CCM2 loss influences cerebral cavernous malformations in mice</article-title><source>Journal of Experimental Medicine</source><volume>208</volume><fpage>1835</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1084/jem.20110571</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname> <given-names>C</given-names></name><name><surname>Arnould</surname> <given-names>M</given-names></name><name><surname>De Luca</surname> <given-names>C</given-names></name><name><surname>Otten</surname> <given-names>C</given-names></name><name><surname>Abdelilah-Seyfried</surname> <given-names>S</given-names></name><name><surname>Heredia</surname> <given-names>A</given-names></name><name><surname>Leutenegger</surname> <given-names>AL</given-names></name><name><surname>Schwaninger</surname> <given-names>M</given-names></name><name><surname>Tournier-Lasserve</surname> <given-names>E</given-names></name><name><surname>Boulday</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Novel chronic mouse model of cerebral cavernous malformations</article-title><source>Stroke</source><volume>51</volume><fpage>1272</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.119.027207</pub-id><pub-id pub-id-type="pmid">31992178</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>AC</given-names></name><name><surname>Drakos</surname> <given-names>SG</given-names></name><name><surname>Ruiz</surname> <given-names>OE</given-names></name><name><surname>Smith</surname> <given-names>ACH</given-names></name><name><surname>Gibson</surname> <given-names>CC</given-names></name><name><surname>Ling</surname> <given-names>J</given-names></name><name><surname>Passi</surname> <given-names>SF</given-names></name><name><surname>Stratman</surname> <given-names>AN</given-names></name><name><surname>Sacharidou</surname> <given-names>A</given-names></name><name><surname>Revelo</surname> <given-names>MP</given-names></name><name><surname>Grossmann</surname> <given-names>AH</given-names></name><name><surname>Diakos</surname> <given-names>NA</given-names></name><name><surname>Davis</surname> <given-names>GE</given-names></name><name><surname>Metzstein</surname> <given-names>MM</given-names></name><name><surname>Whitehead</surname> <given-names>KJ</given-names></name><name><surname>Li</surname> <given-names>DY</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice</article-title><source>Journal of Clinical Investigation</source><volume>121</volume><fpage>1871</fpage><lpage>1881</lpage><pub-id pub-id-type="doi">10.1172/JCI44393</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Mouillesseaux</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Fiji</surname> <given-names>HD</given-names></name><name><surname>Kinderman</surname> <given-names>SS</given-names></name><name><surname>Otto</surname> <given-names>GW</given-names></name><name><surname>Geisler</surname> <given-names>R</given-names></name><name><surname>Kwon</surname> <given-names>O</given-names></name><name><surname>Chen</surname> <given-names>JN</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Aplexone targets the HMG-CoA reductase pathway and differentially regulates arteriovenous angiogenesis</article-title><source>Development</source><volume>138</volume><fpage>1173</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1242/dev.054049</pub-id><pub-id pub-id-type="pmid">21307094</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>EM</given-names></name><name><surname>Bambakidis</surname> <given-names>NC</given-names></name><name><surname>Cohen</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Pathology of cavernous malformations</chapter-title><person-group person-group-type="editor"><name><surname>Cox</surname> <given-names>E. M</given-names></name></person-group><source>Handbook of Clinical Neurology</source><publisher-name>Elsevier</publisher-name><fpage>267</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63640-9.00025-4</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuttano</surname> <given-names>R</given-names></name><name><surname>Rudini</surname> <given-names>N</given-names></name><name><surname>Bravi</surname> <given-names>L</given-names></name><name><surname>Corada</surname> <given-names>M</given-names></name><name><surname>Giampietro</surname> <given-names>C</given-names></name><name><surname>Papa</surname> <given-names>E</given-names></name><name><surname>Morini</surname> <given-names>MF</given-names></name><name><surname>Maddaluno</surname> <given-names>L</given-names></name><name><surname>Baeyens</surname> <given-names>N</given-names></name><name><surname>Adams</surname> <given-names>RH</given-names></name><name><surname>Jain</surname> <given-names>MK</given-names></name><name><surname>Owens</surname> <given-names>GK</given-names></name><name><surname>Schwartz</surname> <given-names>M</given-names></name><name><surname>Lampugnani</surname> <given-names>MG</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>KLF4 is a key determinant in the development and progression of cerebral cavernous malformations</article-title><source>EMBO Molecular Medicine</source><volume>8</volume><fpage>6</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.15252/emmm.201505433</pub-id><pub-id pub-id-type="pmid">26612856</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detter</surname> <given-names>MR</given-names></name><name><surname>Snellings</surname> <given-names>DA</given-names></name><name><surname>Marchuk</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cerebral cavernous malformations develop through clonal expansion of mutant endothelial cells</article-title><source>Circulation Research</source><volume>123</volume><fpage>1143</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.313970</pub-id><pub-id pub-id-type="pmid">30359189</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djonov</surname> <given-names>V</given-names></name><name><surname>Baum</surname> <given-names>O</given-names></name><name><surname>Burri</surname> <given-names>PH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Vascular remodeling by intussusceptive angiogenesis</article-title><source>Cell and Tissue Research</source><volume>314</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1007/s00441-003-0784-3</pub-id><pub-id pub-id-type="pmid">14574551</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egginton</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>AL</given-names></name><name><surname>Brown</surname> <given-names>MD</given-names></name><name><surname>HudlickÃ¡</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Unorthodox angiogenesis in skeletal muscle</article-title><source>Cardiovascular Research</source><volume>49</volume><fpage>634</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(00)00282-0</pub-id><pub-id pub-id-type="pmid">11166277</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galloway</surname> <given-names>JL</given-names></name><name><surname>Wingert</surname> <given-names>RA</given-names></name><name><surname>Thisse</surname> <given-names>C</given-names></name><name><surname>Thisse</surname> <given-names>B</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Loss of gata1 but not gata2 converts erythropoiesis to myelopoiesis in zebrafish embryos</article-title><source>Developmental Cell</source><volume>8</volume><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2004.12.001</pub-id><pub-id pub-id-type="pmid">15621534</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname> <given-names>AR</given-names></name><name><surname>Liu</surname> <given-names>JJ</given-names></name><name><surname>Ginsberg</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural basis of the junctional anchorage of the cerebral cavernous malformations complex</article-title><source>Journal of Cell Biology</source><volume>199</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1083/jcb.201205109</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Goldstein</surname> <given-names>HE</given-names></name><name><surname>Solomon</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Epidemiology of cavernous malformations</chapter-title><person-group person-group-type="editor"><name><surname>Goldstein</surname> <given-names>H. E</given-names></name></person-group><source>Handbook of Clinical Neurology</source><publisher-name>Elsevier</publisher-name><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/B978-0-444-63640-9.00023-0</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gore</surname> <given-names>AV</given-names></name><name><surname>Pillay</surname> <given-names>LM</given-names></name><name><surname>Venero Galanternik</surname> <given-names>M</given-names></name><name><surname>Weinstein</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The zebrafish: a fintastic model for hematopoietic development and disease</article-title><source>WIREs Developmental Biology</source><volume>7</volume><elocation-id>e312</elocation-id><pub-id pub-id-type="doi">10.1002/wdev.312</pub-id><pub-id pub-id-type="pmid">29436122</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>T</given-names></name><name><surname>Mullins</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Dissection of organs from the adult zebrafish</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>1717</elocation-id><pub-id pub-id-type="doi">10.3791/1717</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckel</surname> <given-names>E</given-names></name><name><surname>Boselli</surname> <given-names>F</given-names></name><name><surname>Roth</surname> <given-names>S</given-names></name><name><surname>Krudewig</surname> <given-names>A</given-names></name><name><surname>Belting</surname> <given-names>HG</given-names></name><name><surname>Charvin</surname> <given-names>G</given-names></name><name><surname>Vermot</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Oscillatory flow modulates mechanosensitive klf2a expression through trpv4 and trpp2 during heart valve development</article-title><source>Current Biology</source><volume>25</volume><fpage>1354</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2015.03.038</pub-id><pub-id pub-id-type="pmid">25959969</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jao</surname> <given-names>LE</given-names></name><name><surname>Wente</surname> <given-names>SR</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system</article-title><source>PNAS</source><volume>110</volume><fpage>13904</fpage><lpage>13909</lpage><pub-id pub-id-type="doi">10.1073/pnas.1308335110</pub-id><pub-id pub-id-type="pmid">23918387</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenny Zhou</surname> <given-names>H</given-names></name><name><surname>Qin</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Ji</surname> <given-names>W</given-names></name><name><surname>He</surname> <given-names>Y</given-names></name><name><surname>Liang</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Yuan</surname> <given-names>Q</given-names></name><name><surname>Vortmeyer</surname> <given-names>A</given-names></name><name><surname>Toomre</surname> <given-names>D</given-names></name><name><surname>Fuh</surname> <given-names>G</given-names></name><name><surname>Yan</surname> <given-names>M</given-names></name><name><surname>Kluger</surname> <given-names>MS</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Min</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation</article-title><source>Nature Medicine</source><volume>22</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1038/nm.4169</pub-id><pub-id pub-id-type="pmid">27548575</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>SW</given-names></name><name><surname>Beis</surname> <given-names>D</given-names></name><name><surname>Mitchell</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>JN</given-names></name><name><surname>Stainier</surname> <given-names>DY</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cellular and molecular analyses of vascular tube and lumen formation in zebrafish</article-title><source>Development</source><volume>132</volume><fpage>5199</fpage><lpage>5209</lpage><pub-id pub-id-type="doi">10.1242/dev.02087</pub-id><pub-id pub-id-type="pmid">16251212</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthik</surname> <given-names>S</given-names></name><name><surname>Djukic</surname> <given-names>T</given-names></name><name><surname>Kim</surname> <given-names>JD</given-names></name><name><surname>Zuber</surname> <given-names>B</given-names></name><name><surname>Makanya</surname> <given-names>A</given-names></name><name><surname>Odriozola</surname> <given-names>A</given-names></name><name><surname>Hlushchuk</surname> <given-names>R</given-names></name><name><surname>Filipovic</surname> <given-names>N</given-names></name><name><surname>Jin</surname> <given-names>SW</given-names></name><name><surname>Djonov</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Synergistic interaction of sprouting and intussusceptive angiogenesis during zebrafish caudal vein plexus development</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>9840</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-27791-6</pub-id><pub-id pub-id-type="pmid">29959335</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleaveland</surname> <given-names>B</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Liu</surname> <given-names>JJ</given-names></name><name><surname>Blum</surname> <given-names>Y</given-names></name><name><surname>Tung</surname> <given-names>JJ</given-names></name><name><surname>Zou</surname> <given-names>Z</given-names></name><name><surname>Sweeney</surname> <given-names>SM</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Guo</surname> <given-names>L</given-names></name><name><surname>Lu</surname> <given-names>MM</given-names></name><name><surname>Zhou</surname> <given-names>D</given-names></name><name><surname>Kitajewski</surname> <given-names>J</given-names></name><name><surname>Affolter</surname> <given-names>M</given-names></name><name><surname>Ginsberg</surname> <given-names>MH</given-names></name><name><surname>Kahn</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of cardiovascular development and integrity by the heart of glass-cerebral cavernous malformation protein pathway</article-title><source>Nature Medicine</source><volume>15</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1038/nm.1918</pub-id><pub-id pub-id-type="pmid">19151727</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanfranconi</surname> <given-names>S</given-names></name><name><surname>Scola</surname> <given-names>E</given-names></name><name><surname>Bertani</surname> <given-names>GA</given-names></name><name><surname>Zarino</surname> <given-names>B</given-names></name><name><surname>Pallini</surname> <given-names>R</given-names></name><name><surname>d'Alessandris</surname> <given-names>G</given-names></name><name><surname>Mazzon</surname> <given-names>E</given-names></name><name><surname>Marino</surname> <given-names>S</given-names></name><name><surname>Carriero</surname> <given-names>MR</given-names></name><name><surname>Scelzo</surname> <given-names>E</given-names></name><name><surname>FaragÃ²</surname> <given-names>G</given-names></name><name><surname>Castori</surname> <given-names>M</given-names></name><name><surname>Fusco</surname> <given-names>C</given-names></name><name><surname>Petracca</surname> <given-names>A</given-names></name><name><surname>d'Agruma</surname> <given-names>L</given-names></name><name><surname>Tassi</surname> <given-names>L</given-names></name><name><surname>d'Orio</surname> <given-names>P</given-names></name><name><surname>Lampugnani</surname> <given-names>MG</given-names></name><name><surname>Nicolis</surname> <given-names>EB</given-names></name><name><surname>VasamÃ¬</surname> <given-names>A</given-names></name><name><surname>Novelli</surname> <given-names>D</given-names></name><name><surname>Torri</surname> <given-names>V</given-names></name><name><surname>Meessen</surname> <given-names>J</given-names></name><name><surname>Al-Shahi Salman</surname> <given-names>R</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name><name><surname>Latini</surname> <given-names>R</given-names></name><collab>Treat-CCM Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial</article-title><source>Trials</source><volume>21</volume><elocation-id>401</elocation-id><pub-id pub-id-type="doi">10.1186/s13063-020-4202-x</pub-id><pub-id pub-id-type="pmid">32398113</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname> <given-names>ND</given-names></name><name><surname>Weinstein</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>In vivo imaging of embryonic vascular development using transgenic zebrafish</article-title><source>Developmental Biology</source><volume>248</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1006/dbio.2002.0711</pub-id><pub-id pub-id-type="pmid">12167406</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblanc</surname> <given-names>GG</given-names></name><name><surname>Golanov</surname> <given-names>E</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name><name><surname>Young</surname> <given-names>WL</given-names></name><collab>Biology of Vascular Malformations of the Brain NINDS Workshop Collaborators</collab></person-group><year iso-8601-date="2009">2009</year><article-title>Biology of vascular malformations of the brain</article-title><source>Stroke</source><volume>40</volume><fpage>694</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.109.563692</pub-id><pub-id pub-id-type="pmid">19834013</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>IC</given-names></name><name><surname>Chan</surname> <given-names>CT</given-names></name><name><surname>Lu</surname> <given-names>YF</given-names></name><name><surname>Wu</surname> <given-names>YT</given-names></name><name><surname>Chen</surname> <given-names>YC</given-names></name><name><surname>Li</surname> <given-names>GB</given-names></name><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Hwang</surname> <given-names>SP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Zebrafish KrÃ¼ppel-Like factor 4a represses intestinal cell proliferation and promotes differentiation of intestinal cell lineages</article-title><source>PLOS ONE</source><volume>6</volume><elocation-id>e20974</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0020974</pub-id><pub-id pub-id-type="pmid">21687630</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Detter</surname> <given-names>MR</given-names></name><name><surname>Moore</surname> <given-names>T</given-names></name><name><surname>Benavides</surname> <given-names>C</given-names></name><name><surname>Lightle</surname> <given-names>R</given-names></name><name><surname>Girard</surname> <given-names>R</given-names></name><name><surname>Hobson</surname> <given-names>N</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Griffin</surname> <given-names>E</given-names></name><name><surname>Gallione</surname> <given-names>C</given-names></name><name><surname>Zabramski</surname> <given-names>JM</given-names></name><name><surname>Ginsberg</surname> <given-names>MH</given-names></name><name><surname>Marchuk</surname> <given-names>DA</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Propranolol inhibits cavernous vascular malformations by Î²1 adrenergic receptor antagonism in animal models</article-title><source>Journal of Clinical Investigation</source><volume>131</volume><elocation-id>JCI144893</elocation-id><pub-id pub-id-type="doi">10.1172/JCI144893</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lopez-Ramirez</surname> <given-names>MA</given-names></name><name><surname>Soliman</surname> <given-names>SI</given-names></name><name><surname>Hale</surname> <given-names>P</given-names></name><name><surname>Lai</surname> <given-names>CC</given-names></name><name><surname>Pham</surname> <given-names>A</given-names></name><name><surname>Estrada</surname> <given-names>E</given-names></name><name><surname>McCurdy</surname> <given-names>S</given-names></name><name><surname>Girard</surname> <given-names>R</given-names></name><name><surname>Verma</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>T</given-names></name><name><surname>Lightle</surname> <given-names>R</given-names></name><name><surname>Hobson</surname> <given-names>N</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Poulsen</surname> <given-names>O</given-names></name><name><surname>Haddad</surname> <given-names>GG</given-names></name><name><surname>Daneman</surname> <given-names>R</given-names></name><name><surname>Gongol, H</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Non cell-autonomous effect of astrocytes on cerebral cavernous malformations</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.01.29.428891</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mably</surname> <given-names>JD</given-names></name><name><surname>Chuang</surname> <given-names>LP</given-names></name><name><surname>Serluca</surname> <given-names>FC</given-names></name><name><surname>Mohideen</surname> <given-names>MA</given-names></name><name><surname>Chen</surname> <given-names>JN</given-names></name><name><surname>Fishman</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title><italic>Santa</italic> and <italic>valentine</italic> pattern concentric growth of cardiac myocardium in the zebrafish</article-title><source>Development</source><volume>133</volume><fpage>3139</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1242/dev.02469</pub-id><pub-id pub-id-type="pmid">16873582</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malinverno</surname> <given-names>M</given-names></name><name><surname>Maderna</surname> <given-names>C</given-names></name><name><surname>Abu Taha</surname> <given-names>A</given-names></name><name><surname>Corada</surname> <given-names>M</given-names></name><name><surname>Orsenigo</surname> <given-names>F</given-names></name><name><surname>Valentino</surname> <given-names>M</given-names></name><name><surname>Pisati</surname> <given-names>F</given-names></name><name><surname>Fusco</surname> <given-names>C</given-names></name><name><surname>Graziano</surname> <given-names>P</given-names></name><name><surname>Giannotta</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>QC</given-names></name><name><surname>Zeng</surname> <given-names>YA</given-names></name><name><surname>Lampugnani</surname> <given-names>MG</given-names></name><name><surname>Magnusson</surname> <given-names>PU</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endothelial cell clonal expansion in the development of cerebral cavernous malformations</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2761</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10707-x</pub-id><pub-id pub-id-type="pmid">31235698</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname> <given-names>DA</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Shi</surname> <given-names>C</given-names></name><name><surname>Stockton</surname> <given-names>RA</given-names></name><name><surname>Akers</surname> <given-names>AL</given-names></name><name><surname>Kucherlapati</surname> <given-names>MH</given-names></name><name><surname>Kucherlapati</surname> <given-names>R</given-names></name><name><surname>Brainer</surname> <given-names>J</given-names></name><name><surname>Ginsberg</surname> <given-names>MH</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name><name><surname>Marchuk</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease</article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>211</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq433</pub-id><pub-id pub-id-type="pmid">20940147</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname> <given-names>DA</given-names></name><name><surname>Shi</surname> <given-names>C</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Stockton</surname> <given-names>RA</given-names></name><name><surname>Liu</surname> <given-names>F</given-names></name><name><surname>Ginsberg</surname> <given-names>MH</given-names></name><name><surname>Marchuk</surname> <given-names>DA</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease</article-title><source>Stroke</source><volume>43</volume><fpage>571</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.111.625467</pub-id><pub-id pub-id-type="pmid">22034008</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikati</surname> <given-names>AG</given-names></name><name><surname>Khanna</surname> <given-names>O</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Girard</surname> <given-names>R</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Shah</surname> <given-names>A</given-names></name><name><surname>Larsson</surname> <given-names>HB</given-names></name><name><surname>Tan</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wishnoff</surname> <given-names>MS</given-names></name><name><surname>Shi</surname> <given-names>C</given-names></name><name><surname>Christoforidis</surname> <given-names>GA</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Vascular permeability in cerebral cavernous malformations</article-title><source>Journal of Cerebral Blood Flow &amp; Metabolism</source><volume>35</volume><fpage>1632</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2015.98</pub-id><pub-id pub-id-type="pmid">25966944</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monteiro</surname> <given-names>R</given-names></name><name><surname>Pouget</surname> <given-names>C</given-names></name><name><surname>Patient</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1Î³</article-title><source>The EMBO Journal</source><volume>30</volume><fpage>1093</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.34</pub-id><pub-id pub-id-type="pmid">21336259</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname> <given-names>N</given-names></name><name><surname>Schaffer</surname> <given-names>CB</given-names></name><name><surname>Friedman</surname> <given-names>B</given-names></name><name><surname>Tsai</surname> <given-names>PS</given-names></name><name><surname>Lyden</surname> <given-names>PD</given-names></name><name><surname>Kleinfeld</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Targeted insult to subsurface cortical blood vessels using ultrashort laser pulses: three models of stroke</article-title><source>Nature Methods</source><volume>3</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1038/nmeth844</pub-id><pub-id pub-id-type="pmid">16432519</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oates</surname> <given-names>AC</given-names></name><name><surname>Pratt</surname> <given-names>SJ</given-names></name><name><surname>Vail</surname> <given-names>B</given-names></name><name><surname>Yan</surname> <given-names>Y-L</given-names></name><name><surname>Ho</surname> <given-names>RK</given-names></name><name><surname>Johnson</surname> <given-names>SL</given-names></name><name><surname>Postlethwait</surname> <given-names>JH</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The zebrafish klf gene family</article-title><source>Blood</source><volume>98</volume><fpage>1792</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1182/blood.V98.6.1792</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname> <given-names>J</given-names></name><name><surname>Malinverno</surname> <given-names>M</given-names></name><name><surname>Globisch</surname> <given-names>MA</given-names></name><name><surname>Maderna</surname> <given-names>C</given-names></name><name><surname>Corada</surname> <given-names>M</given-names></name><name><surname>Orsenigo</surname> <given-names>F</given-names></name><name><surname>Conze</surname> <given-names>LL</given-names></name><name><surname>Rorsman</surname> <given-names>C</given-names></name><name><surname>Sundell</surname> <given-names>V</given-names></name><name><surname>Arce</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>RO</given-names></name><name><surname>Yau</surname> <given-names>ACY</given-names></name><name><surname>BillstrÃ¶m</surname> <given-names>GH</given-names></name><name><surname>MÃ¤gi</surname> <given-names>CÃ</given-names></name><name><surname>Beznoussenko</surname> <given-names>GV</given-names></name><name><surname>Mironov</surname> <given-names>AA</given-names></name><name><surname>Fernando</surname> <given-names>D</given-names></name><name><surname>Daniel</surname> <given-names>G</given-names></name><name><surname>Olivari</surname> <given-names>D</given-names></name><name><surname>Fumagalli</surname> <given-names>F</given-names></name><name><surname>Lampugnani</surname> <given-names>MG</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name><name><surname>Magnusson</surname> <given-names>PU</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Propranolol reduces the development of lesions and rescues barrier function in cerebral cavernous malformations: a preclinical study</article-title><source>Stroke</source><volume>52</volume><fpage>1418</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.120.029676</pub-id><pub-id pub-id-type="pmid">33618555</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otten</surname> <given-names>C</given-names></name><name><surname>Knox</surname> <given-names>J</given-names></name><name><surname>Boulday</surname> <given-names>G</given-names></name><name><surname>Eymery</surname> <given-names>M</given-names></name><name><surname>Haniszewski</surname> <given-names>M</given-names></name><name><surname>Neuenschwander</surname> <given-names>M</given-names></name><name><surname>Radetzki</surname> <given-names>S</given-names></name><name><surname>Vogt</surname> <given-names>I</given-names></name><name><surname>HÃ¤hn</surname> <given-names>K</given-names></name><name><surname>De Luca</surname> <given-names>C</given-names></name><name><surname>Cardoso</surname> <given-names>C</given-names></name><name><surname>Hamad</surname> <given-names>S</given-names></name><name><surname>Igual Gil</surname> <given-names>C</given-names></name><name><surname>Roy</surname> <given-names>P</given-names></name><name><surname>AlbigesâRizo</surname> <given-names>C</given-names></name><name><surname>Faurobert</surname> <given-names>E</given-names></name><name><surname>Kries</surname> <given-names>JP</given-names></name><name><surname>Campillos</surname> <given-names>M</given-names></name><name><surname>TournierâLasserve</surname> <given-names>E</given-names></name><name><surname>Derry</surname> <given-names>WB</given-names></name><name><surname>AbdelilahâSeyfried</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations</article-title><source>EMBO Molecular Medicine</source><volume>10</volume><elocation-id>201809155</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.201809155</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parmar</surname> <given-names>KM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2</article-title><source>Journal of Clinical Investigation</source><volume>116</volume><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1172/JCI24787</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhard</surname> <given-names>M</given-names></name><name><surname>Schuchardt</surname> <given-names>F</given-names></name><name><surname>Meckel</surname> <given-names>S</given-names></name><name><surname>Heinz</surname> <given-names>J</given-names></name><name><surname>Felbor</surname> <given-names>U</given-names></name><name><surname>Sure</surname> <given-names>U</given-names></name><name><surname>Geisen</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Propranolol stops progressive multiple cerebral cavernoma in an adult patient</article-title><source>Journal of the Neurological Sciences</source><volume>367</volume><fpage>15</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2016.04.053</pub-id><pub-id pub-id-type="pmid">27423555</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renz</surname> <given-names>M</given-names></name><name><surname>Otten</surname> <given-names>C</given-names></name><name><surname>Faurobert</surname> <given-names>E</given-names></name><name><surname>Rudolph</surname> <given-names>F</given-names></name><name><surname>Zhu</surname> <given-names>Y</given-names></name><name><surname>Boulday</surname> <given-names>G</given-names></name><name><surname>Duchene</surname> <given-names>J</given-names></name><name><surname>Mickoleit</surname> <given-names>M</given-names></name><name><surname>Dietrich</surname> <given-names>AC</given-names></name><name><surname>Ramspacher</surname> <given-names>C</given-names></name><name><surname>Steed</surname> <given-names>E</given-names></name><name><surname>Manet-DupÃ©</surname> <given-names>S</given-names></name><name><surname>Benz</surname> <given-names>A</given-names></name><name><surname>Hassel</surname> <given-names>D</given-names></name><name><surname>Vermot</surname> <given-names>J</given-names></name><name><surname>Huisken</surname> <given-names>J</given-names></name><name><surname>Tournier-Lasserve</surname> <given-names>E</given-names></name><name><surname>Felbor</surname> <given-names>U</given-names></name><name><surname>Sure</surname> <given-names>U</given-names></name><name><surname>Albiges-Rizo</surname> <given-names>C</given-names></name><name><surname>Abdelilah-Seyfried</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of Î²1 integrin-Klf2-mediated angiogenesis by CCM proteins</article-title><source>Developmental Cell</source><volume>32</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.12.016</pub-id><pub-id pub-id-type="pmid">25625207</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>RÃ¶del</surname> <given-names>CJ</given-names></name><name><surname>Otten</surname> <given-names>C</given-names></name><name><surname>Donat</surname> <given-names>S</given-names></name><name><surname>LourenÃ§o</surname> <given-names>M</given-names></name><name><surname>Fischer</surname> <given-names>D</given-names></name><name><surname>Kuropka</surname> <given-names>B</given-names></name><name><surname>Paolini</surname> <given-names>A</given-names></name><name><surname>Freund</surname> <given-names>C</given-names></name><name><surname>Abdelilah-Seyfried</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Blood flow suppresses vascular anomalies in a zebrafish model of cerebral cavernous malformations</article-title><source>Circulation Research</source><volume>125</volume><fpage>e43</fpage><lpage>e54</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.315076</pub-id><pub-id pub-id-type="pmid">31495257</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname> <given-names>BL</given-names></name><name><surname>Pham</surname> <given-names>VN</given-names></name><name><surname>Lawson</surname> <given-names>ND</given-names></name><name><surname>Kulik</surname> <given-names>M</given-names></name><name><surname>Childs</surname> <given-names>S</given-names></name><name><surname>Lekven</surname> <given-names>AC</given-names></name><name><surname>Garrity</surname> <given-names>DM</given-names></name><name><surname>Moon</surname> <given-names>RT</given-names></name><name><surname>Fishman</surname> <given-names>MC</given-names></name><name><surname>Lechleider</surname> <given-names>RJ</given-names></name><name><surname>Weinstein</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Disruption of <italic>acvrl1</italic> increases endothelial cell number in zebrafish cranial vessels</article-title><source>Development</source><volume>129</volume><fpage>3009</fpage><lpage>3019</lpage><pub-id pub-id-type="doi">10.1242/dev.129.12.3009</pub-id><pub-id pub-id-type="pmid">12050147</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname> <given-names>S</given-names></name><name><surname>Gaetzner</surname> <given-names>S</given-names></name><name><surname>Voss</surname> <given-names>K</given-names></name><name><surname>Brackertz</surname> <given-names>B</given-names></name><name><surname>Schleider</surname> <given-names>E</given-names></name><name><surname>SÃ¼rÃ¼cÃ¼</surname> <given-names>O</given-names></name><name><surname>Kunze</surname> <given-names>E</given-names></name><name><surname>Netzer</surname> <given-names>C</given-names></name><name><surname>Korenke</surname> <given-names>C</given-names></name><name><surname>Finckh</surname> <given-names>U</given-names></name><name><surname>Habek</surname> <given-names>M</given-names></name><name><surname>Poljakovic</surname> <given-names>Z</given-names></name><name><surname>Elbracht</surname> <given-names>M</given-names></name><name><surname>Rudnik-SchÃ¶neborn</surname> <given-names>S</given-names></name><name><surname>Bertalanffy</surname> <given-names>H</given-names></name><name><surname>Sure</surname> <given-names>U</given-names></name><name><surname>Felbor</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex</article-title><source>Human Mutation</source><volume>29</volume><fpage>709</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1002/humu.20712</pub-id><pub-id pub-id-type="pmid">18300272</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stainier</surname> <given-names>DYR</given-names></name><name><surname>Raz</surname> <given-names>E</given-names></name><name><surname>Lawson</surname> <given-names>ND</given-names></name><name><surname>Ekker</surname> <given-names>SC</given-names></name><name><surname>Burdine</surname> <given-names>RD</given-names></name><name><surname>Eisen</surname> <given-names>JS</given-names></name><name><surname>Ingham</surname> <given-names>PW</given-names></name><name><surname>Schulte-Merker</surname> <given-names>S</given-names></name><name><surname>Yelon</surname> <given-names>D</given-names></name><name><surname>Weinstein</surname> <given-names>BM</given-names></name><name><surname>Mullins</surname> <given-names>MC</given-names></name><name><surname>Wilson</surname> <given-names>SW</given-names></name><name><surname>Ramakrishnan</surname> <given-names>L</given-names></name><name><surname>Amacher</surname> <given-names>SL</given-names></name><name><surname>Neuhauss</surname> <given-names>SCF</given-names></name><name><surname>Meng</surname> <given-names>A</given-names></name><name><surname>Mochizuki</surname> <given-names>N</given-names></name><name><surname>Panula</surname> <given-names>P</given-names></name><name><surname>Moens</surname> <given-names>CB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Guidelines for morpholino use in zebrafish</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1007000</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1007000</pub-id><pub-id pub-id-type="pmid">29049395</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steed</surname> <given-names>E</given-names></name><name><surname>Faggianelli</surname> <given-names>N</given-names></name><name><surname>Roth</surname> <given-names>S</given-names></name><name><surname>Ramspacher</surname> <given-names>C</given-names></name><name><surname>Concordet</surname> <given-names>J-P</given-names></name><name><surname>Vermot</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>klf2a couples mechanotransduction and zebrafish valve morphogenesis through fibronectin synthesis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11646</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11646</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Susaki</surname> <given-names>EA</given-names></name><name><surname>Tainaka</surname> <given-names>K</given-names></name><name><surname>Perrin</surname> <given-names>D</given-names></name><name><surname>Yukinaga</surname> <given-names>H</given-names></name><name><surname>Kuno</surname> <given-names>A</given-names></name><name><surname>Ueda</surname> <given-names>HR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging</article-title><source>Nature Protocols</source><volume>10</volume><fpage>1709</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1038/nprot.2015.085</pub-id><pub-id pub-id-type="pmid">26448360</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thisse</surname> <given-names>C</given-names></name><name><surname>Thisse</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>High-resolution in situ hybridization to whole-mount zebrafish embryos</article-title><source>Nature Protocols</source><volume>3</volume><fpage>59</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.514</pub-id><pub-id pub-id-type="pmid">18193022</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traver</surname> <given-names>D</given-names></name><name><surname>Paw</surname> <given-names>BH</given-names></name><name><surname>Poss</surname> <given-names>KD</given-names></name><name><surname>Penberthy</surname> <given-names>WT</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants</article-title><source>Nature Immunology</source><volume>4</volume><fpage>1238</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1038/ni1007</pub-id><pub-id pub-id-type="pmid">14608381</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>RM</given-names></name><name><surname>Sessa</surname> <given-names>A</given-names></name><name><surname>Burke</surname> <given-names>C</given-names></name><name><surname>Bowman</surname> <given-names>T</given-names></name><name><surname>LeBlanc</surname> <given-names>J</given-names></name><name><surname>Ceol</surname> <given-names>C</given-names></name><name><surname>Bourque</surname> <given-names>C</given-names></name><name><surname>Dovey</surname> <given-names>M</given-names></name><name><surname>Goessling</surname> <given-names>W</given-names></name><name><surname>Burns</surname> <given-names>CE</given-names></name><name><surname>Zon</surname> <given-names>LI</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transparent adult zebrafish as a tool for in vivo transplantation analysis</article-title><source>Cell Stem Cell</source><volume>2</volume><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.11.002</pub-id><pub-id pub-id-type="pmid">18371439</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoruk</surname> <given-names>B</given-names></name><name><surname>Gillers</surname> <given-names>BS</given-names></name><name><surname>Chi</surname> <given-names>NC</given-names></name><name><surname>Scott</surname> <given-names>IC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ccm3 functions in a manner distinct from Ccm1 and Ccm2 in a zebrafish model of CCM vascular disease</article-title><source>Developmental Biology</source><volume>362</volume><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2011.12.006</pub-id><pub-id pub-id-type="pmid">22182521</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeineddine</surname> <given-names>HA</given-names></name><name><surname>Girard</surname> <given-names>R</given-names></name><name><surname>Saadat</surname> <given-names>L</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Lightle</surname> <given-names>R</given-names></name><name><surname>Moore</surname> <given-names>T</given-names></name><name><surname>Cao</surname> <given-names>Y</given-names></name><name><surname>Hobson</surname> <given-names>N</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Avner</surname> <given-names>K</given-names></name><name><surname>Chaudager</surname> <given-names>K</given-names></name><name><surname>KoskimÃ¤ki</surname> <given-names>J</given-names></name><name><surname>Polster</surname> <given-names>SP</given-names></name><name><surname>Fam</surname> <given-names>MD</given-names></name><name><surname>Shi</surname> <given-names>C</given-names></name><name><surname>Lopez-Ramirez</surname> <given-names>MA</given-names></name><name><surname>Tang</surname> <given-names>AT</given-names></name><name><surname>Gallione</surname> <given-names>C</given-names></name><name><surname>Kahn</surname> <given-names>ML</given-names></name><name><surname>Ginsberg</surname> <given-names>M</given-names></name><name><surname>Marchuk</surname> <given-names>DA</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Phenotypic characterization of murine models of cerebral cavernous malformations</article-title><source>Laboratory Investigation</source><volume>99</volume><fpage>319</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/s41374-018-0030-y</pub-id><pub-id pub-id-type="pmid">29946133</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Riant</surname> <given-names>F</given-names></name><name><surname>Bergametti</surname> <given-names>F</given-names></name><name><surname>Myers</surname> <given-names>CD</given-names></name><name><surname>Tang</surname> <given-names>AT</given-names></name><name><surname>Kleaveland</surname> <given-names>B</given-names></name><name><surname>Pan</surname> <given-names>W</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Tournier-Lasserve</surname> <given-names>E</given-names></name><name><surname>Kahn</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cerebral cavernous malformations arise independent of the heart of glass receptor</article-title><source>Stroke</source><volume>45</volume><fpage>1505</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.114.004809</pub-id><pub-id pub-id-type="pmid">24643410</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Rawnsley</surname> <given-names>DR</given-names></name><name><surname>Goddard</surname> <given-names>LM</given-names></name><name><surname>Pan</surname> <given-names>W</given-names></name><name><surname>Cao</surname> <given-names>XJ</given-names></name><name><surname>Jakus</surname> <given-names>Z</given-names></name><name><surname>Zheng</surname> <given-names>H</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Arthur</surname> <given-names>JS</given-names></name><name><surname>Whitehead</surname> <given-names>KJ</given-names></name><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Zhou</surname> <given-names>B</given-names></name><name><surname>Garcia</surname> <given-names>BA</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Kahn</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression</article-title><source>Developmental Cell</source><volume>32</volume><fpage>168</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.12.009</pub-id><pub-id pub-id-type="pmid">25625206</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Z</given-names></name><name><surname>Tang</surname> <given-names>AT</given-names></name><name><surname>Wong</surname> <given-names>W-Y</given-names></name><name><surname>Bamezai</surname> <given-names>S</given-names></name><name><surname>Goddard</surname> <given-names>LM</given-names></name><name><surname>Shenkar</surname> <given-names>R</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>J</given-names></name><name><surname>Wright</surname> <given-names>AC</given-names></name><name><surname>Foley</surname> <given-names>M</given-names></name><name><surname>Arthur</surname> <given-names>JSC</given-names></name><name><surname>Whitehead</surname> <given-names>KJ</given-names></name><name><surname>Awad</surname> <given-names>IA</given-names></name><name><surname>Li</surname> <given-names>DY</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Kahn</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cerebral cavernous malformations arise from endothelial gain of MEKK3âKLF2/4 signalling</article-title><source>Nature</source><volume>532</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nature17178</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.62155.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Dejana</surname><given-names>Elisabetta</given-names></name><role>Reviewing Editor</role><aff><institution>FIRC Institute of Molecular Oncology Foundationtion (IFOM)</institution><country>Italy</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Bautch</surname><given-names>Victoria L</given-names></name><role>Reviewer</role><aff><institution>University of North Carolina, Chapel Hill</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Derry</surname><given-names>Brent</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>Thank you for submitting your article &quot;Abortive Intussusceptive Angiogenesis Causes Multi-Cavernous Vascular Malformations&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 4 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Edward Morrisey as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Victoria L Bautch (Reviewer #2); Brent Derry (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>All the reviewers agree that the paper has potential but they also ask for relevant revision. More specifically:</p><p>1. A detailed discussion on the working hypothesis on the role of flow and mosaicism on CCM lesion development.</p><p>2. The use of the fish model presented here for a high throughput screening of thousands of drugs looks indeed a very difficult if not impossible task. Would the authors be able to answer to this criticism?</p><p>3. Statistic is also poor and, in many cases, missing. This is a crucial aspect of the study and should be better reported and described.</p><p>The paper therefore warrants publication in <italic>eLife</italic> but revision is needed. Please see the full reviews below for further comments.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p><italic>Reviewer #1:</italic></p><p>Li et al. present a new model of CCM in Z.fish using mosaic inactivation of ccm2 through Crisp technique. Vascular malformations develop in the Caudal venous plexus in the embryos and in the central nervous system of the embryos surviving to adulthood.</p><p>These malformations in the Caudal venous plexus form for aberrant intussusception and depend on flow, accumulation of erythrocytes and mosaic upregulation of klf2.</p><p>The authors propose this model for large pharmacological screening of CCM phenotype-correcting drugs. The first step would test compounds on malformations in the Caudal venous plexus of Z. fish embryos. The following validation step would test the malformations in the CNS of the mutant adults.</p><p>The model is skillfully presented. However, the interpretation of the mechanism is not fully supported by the experimental data which appear often more suggestive than conclusive.</p><p>1. The morphological features and some of the mechanisms directing the formation of vascular malformations in Z. fish embryos are studied in details, while those in the central nervous system of adults are only shown to depend on the expression of klf2. To which extent is the mechanism driving the lesions in the Caudal venous plexus modeling that in the CNS?</p><p>Are the lesions in the CNS depending on blood flow and erythrocyte accumulation and do they show abortive intussusception as in the Caudal venous plexus? In addition, do vascular malformations in the Caudal venous plexus show increased permeability and hemorrhages as those in the CNS? Organ-specific microenvironment strongly influences endothelial responses. Therefore, the issues above should be defined for comprehensively describe the biology of the model and for supporting the validity of the two-step screening proposed.</p><p>Most importantly, the limits of the intussusceptive mechanism of lesion formation in Z. fish Caudal venous plexus as a model for human cavernomas in the CNS are neither tested nor demonstrated.</p><p>2. While the advantages of using Z. fish for direct and rapid in vivo analysis of CCM lesions is appealing some caveats are evident. Is Z. fish equally sensitive to mosaic deletion of ccm1 and ccm3 as to ccm2? The literature about the effects of mutation of CCM genes in Z. fish, well summarized by the authors, indicates that Z. fish could react in a peculiar way to the mutation of different CCM genes. This can limit the use of Z. fish as a model of human cavernomas.</p><p>3. 'Mosaic upregulation of KLF2a is sufficient for cavernoma formation in CVP'.</p><p>Mosaic upregulation of klf2 induces malformation in the Caudal venous plexus in 6% of the embryos. This is a small percentage compared to 30% ccm2 Crisp embryos developing malformations in Caudal venous plexus. This different efficiency should be explained.</p><p>Is the level of overexpressed klf2 in the range reached by klf2 after ccm2 deletion? Where is this overexpressed klf2 actually localized? Is this overexpressed klf2 localized in the pillars of the vascular malformation? Is the endogenous klf2 upregulated in the pillars of the vascular malformations of ccm2 Crisp embryos? This is not visible in Figure 4D. In addition, is the mosaic increase of klf2 able to induce malformations in the CNS in the adult?</p><p>4. Do the malformations contain ccm2 null endothelial cells? No direct evidence is presented, besides the rescuing of the dilated CVP phenotype by ccm2-mRNA. Do the lesion-free areas of the Caudal venous plexus contain equal density of ccm2 null endothelial cells as in lesion areas?</p><p>5. Statistical analysis needs be shown to support the reproducibility of the data presented in Figure 3 E and F. Which was the range of reduction of vein diameter after pillar ablation and how many embryos were used to reproduce this result? This aspect needs to be strengthened has much of the model interpretation is based on the role of intraluminal pillar in obstructing blood flow and causing vessel dilation.</p><p>6. In several figures presenting morphologic data statistical analysis is missing and should be added. Figure 6A, B, C quantification of the immunofluorescence results is lacking. How many endothelial cells show upregulation of klf2 in ccm2 Crisp? No control of Figure 6B is shown.</p><p>7. How would erythrocytes contribute to the formation/dilation of the cavernae? Would this be a mechanical effect or would erythrocytes convey other signals to endothelial cells? Are erythrocytes present in the cavernae ccm2 null?</p><p>8. It is not clear what come first: both erythrocyte null and heart-silenced ccm2 crisp show reduction of dilated CVP. Do erythrocytes circulate in silenced heart Z. fish? In addition, how is klf2 regulated in erythrocytes null and heart-silenced ccm2 Crisp Z. fish?</p><p>9. Are the embryos developing malformations in the CVP surviving? If yes, are the cavernoma in the Caudal venous plexus persisting?</p><p>10. When and how do the cavernomas form in the brain of the surviving fishes? This is a significant aspect to define in this model, as cavernomas in the central nervous system are the malformations with pathological consequences in humans. How long do these mutant adults survive?</p><p>11. In murine models klf4 is also required for cavernoma formation. Is the same true for Z. fish?</p><p><italic>Reviewer #2:</italic></p><p>The paper by Li et al. investigates the effects of mosaic manipulation of CCM2 in zebrafish embryos and adult fish, and describes a CVP dilation linked to intussusceptive angiogenesis in embryos and neurovascular lesions in adult fish. The primary finding is that mosaic deletion of CCM2 leads to differences in flow-mediated responses of EC that lead to the embryonic phenotype, and that it occurs in the context of intussusceptive angiogenesis. These findings are well-supported by genetic, morpholino (MO) and pharmacological analysis and overall careful and rigorous analysis. The novelty is substantial in both findings and experimental approach (CRISPR/Cas induced mosaicism) and provides explanations for some of the disease phenotypes. However, there are some issues that, if addressed, would substantially improve the work:</p><p>1. I understand why the adult phenotype is presented, and it does show validity of the adult fish as a model. However, in terms of mechanism, it raises interesting questions that were not adequately addressed â for example, how do lesions form in a tissue that is not known to undergo intussusceptive angiogenesis? Is Klf2 expression also mosaic in the adult fish brains? Can the fish be used to generate mosaic Klf2 over-expression and determine effects in the adult independent of CCM2 manipulation?</p><p>2. Many of the statements regarding the data in the Results and Discussion are stated as facts rather than presented as conclusions â there are too many to enumerate, but examples: p. 18: &quot;first zebrafish model of CCM&quot;; p. 19: &quot;pillars failedâ¦to split due to mosaic over-expression of klf2aâ¦.&quot;. The work is very rigorous but all experiments have caveats. The Discussion is also very focused on why the adult fish is a good model for clinical CCM, and many interesting aspects of the bulk of the work presented in the embryo are not addressed. For example, why is mosaic loss but not global loss of flow-sensing proposed to lead to the phenotype? Are the mechanisms the same in vessel beds that do not undergo intussusceptive angiogenesis? What is the effect of the CCM complex vs. CCM2 alone?</p><p>3. The work is quite novel and exciting; however, it is difficult to keep track of the different manipulations and combination of manipulations, and this is exacerbated by very poor labeling of figures and descriptions in figure legends. Many of the Y-axis labels merely say &quot;% phenotype&quot; with no context for complex combinations of manipulations. Images are not well labeled for stains/reporters. There is no documentation that most experiments were mosaic for deletion, which is central to the model put forward â the labels suggest global LOF. Suggest use (or figure out if this is new) a nomenclature for mosaic deletion and use consistently. Please be clear about GOF vs. LOF manipulations.</p><p><italic>Reviewer #3:</italic></p><p>This manuscript describes a mosaic model of ccm2 deletion in zebrafish. The authors report defects in the vasculature including dilations in the caudal venous plexus (CVP) and cranial vessels (CV), as well as previously described vascular and heart defects. Confocal imaging and 3D reconstruction showed defective lumenization of endothelial pillars, resulting in multiple chambers that accumulate blood and suggest incomplete intussusceptive angiogenesis. Laser ablation of defective pillars relieved dilation and restored blood flow, suggesting that the pillars caused dilated CVP and flow defects. They demonstrate that blood flow is required for the dilation of CVP and intussusceptive pillar formation in mosaic ccm2 mosaics, which casts doubt on a recent study showing that blood flow actually suppresses vascular anomalies in zebrafish harboring a germline krit1 (CCM1) knockout (PMID: 31495257). Furthermore, they show that erythrocyte accumulation in defective CVP drives their dilation. They convincingly demonstrate that mosaicism accounts for CVP dilation by co-injection of a sublethal dose of ccm2 morpholino with the CRISPR mix. They go on to show that upregulation of the Klf2 transcription factor, which acts downstream of Ccm2, accounts for dilation of CVP in ccm2 mosaic mutants. This impedes the flow signaling required for intussusceptive angiogenesis that remodels the CVP and likely explains how these lesions form in human CCM patients. Finally, ccm2 mosaic fish that did not exhibit vascular anomalies eventually develop lesions in their brain vasculature and spinal cords by adulthood. This study shows that mosaicism is a pre-requisite for formation of multi-cavernous lesions and provides the first zebrafish model that accurately recapitulates the disease in humans. This is an important advance in our understanding of the genesis of CCM lesions that should be suitable for publication after a few concerns are addressed.</p><p>1. Do actin stress fibers form and/or does pMLC increase in endothelial cells of lesions? This would highlight conservation of CCM lesion mechanisms between fish and human.</p><p>2. Since the authors have previously shown that inhibition of Rho kinase can suppress lesion formation in mouse models it would be nice to see if this is also true in their mosaic zebrafish model.</p><p>3. While the authors show that mosaic overexpression of klf2a is responsible for the formation of vascular defects in the CVP of ccm2 mosaic fish, they do not show this when Ccm2 is overexpressed (Figure 5B). Therefore, they should inject linearized ccm2 fused to mOrange into the klf2a mutants to see if these embryos also fail to develop CVP dilations.</p><p>4. In the text the authors state that CCM lesions were not observed when ccm2 was edited in klf2a-/- mutants, but in Figure 7P they report 1/10 embryos with lesions. The text should be amended to reflect this result, as it misrepresents their conclusions.</p><p>5. There has been a bit of controversy in the zebrafish community regarding the use of &quot;Crispants&quot; and morpholinos versus germline mutants that the authors should acknowledge (ie PMID: 32968253). I have no issues with the interpretation of data in this study since they performed rescue experiments but given the differences in phenotypes compared with germline mutants this needs to be discussed.</p><p><italic>Reviewer #4:</italic></p><p>Wenqing Li et al. introduce a novel mechanism that may cooperate in the formation of malberry vascular development in CCM2 deficient Zebra fish. These authors claim that in the caudal venous plexus, mosaic inactivation of CCM2 together with a patchy upregulation of klf2a results in the formation of pillars that create a partial obstruction of the blood flow due to red cell accumulation in the lumen. Morphologically, the pillars mimic intussusceptive angiogenesis and this alters the correct development of the vasculature. In CCM deficient fish the pillars are unable to fully cross the lumen and create multi-cavernous malberry-like malformations. Overall, these morphological observations are of interest and introduce partially novel concepts.</p><p>However:</p><p>â I am not convinced that this model is better than the mouse models available. It is a complex, time limited and variable condition. The percentage of fish resulting affected is relatively low and this prevents the use of this model for high throughput screening of thousands of compounds, as proposed by the authors.</p><p>â Not all the conclusions are substantiated by previous work in the mouse. For instance, the authors underline that klf2a is the major effector of cavernoma formation in the fish, while in mice klf4 is equally or even more important.</p><p>â Most importantly, there are no data showing that the formation of pillars and abortive angiogenesis also occur in CCM2 deficient mammals.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.62155.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[â¦] The model is skillfully presented. However, the interpretation of the mechanism is not fully supported by the experimental data which appear often more suggestive than conclusive.</p><p>1. The morphological features and some of the mechanisms directing the formation of vascular malformations in Z. fish embryos are studied in details, while those in the central nervous system of adults are only shown to depend on the expression of klf2. To which extent is the mechanism driving the lesions in the Caudal venous plexus modeling that in the CNS?</p></disp-quote><p>Our data show that both CNS and CVP lesions arise following mosaic inactivation of a CCM gene and depend on <italic>klf2a.</italic> We agree that there are important differences between the environment of the brain and the CVP and have inserted the following comment to emphasize this point: âThat said, the CVP does lack CNS accessory cells, such as astrocytes,(Lopez-Ramirez et al., 2021) that promote CCM development.â We have also cited a recently published report that development of the CVP lesion, like the brain CCM, is inhibited by propranolol. Our previous work showed that blocking Rho Kinase would decrease CCM in a mouse model and, in an experiment suggested by referee 3, we now show that blocking Rho Kinase inhibits the CVP lesion (Figure 7âfigure supplement 2).</p><disp-quote content-type="editor-comment"><p>Are the lesions in the CNS depending on blood flow and erythrocyte accumulation and do they show abortive intussusception as in the Caudal venous plexus? In addition, do vascular malformations in the Caudal venous plexus show increased permeability and hemorrhages as those in the CNS? Organ-specific microenvironment strongly influences endothelial responses. Therefore, the issues above should be defined for comprehensively describe the biology of the model and for supporting the validity of the two-step screening proposed.</p><p>Most importantly, the limits of the intussusceptive mechanism of lesion formation in Z. fish Caudal venous plexus as a model for human cavernomas in the CNS are neither tested nor demonstrated.</p></disp-quote><p>Addressing this concern would require imaging the human disease at high resolution as it develops, which is presently not technically feasible.</p><disp-quote content-type="editor-comment"><p>2. While the advantages of using Z. fish for direct and rapid in vivo analysis of CCM lesions is appealing some caveats are evident. Is Z. fish equally sensitive to mosaic deletion of ccm1 and ccm3 as to ccm2? The literature about the effects of mutation of CCM genes in Z. fish, well summarized by the authors, indicates that Z. fish could react in a peculiar way to the mutation of different CCM genes. This can limit the use of Z. fish as a model of human cavernomas.</p></disp-quote><p>We have not been able to identify candidate guide RNAs for <italic>ccm3.</italic> Five candidate <italic>ccm1</italic> guide RNAs (Reviewer Table) failed to produce sufficient indels. We were therefore unable to do these experiments; however, we note that CCM1 and CCM2 function as a complex and the phenotypic effects of their loss in mammals and zebrafish have been indistinguishable.</p><disp-quote content-type="editor-comment"><p>3. 'Mosaic upregulation of KLF2a is sufficient for cavernoma formation in CVP'.</p><p>Mosaic upregulation of klf2 induces malformation in the Caudal venous plexus in 6% of the embryos. This is a small percentage compared to 30% ccm2 Crisp embryos developing malformations in Caudal venous plexus. This different efficiency should be explained.</p></disp-quote><p>The degree and sites of mosaicism in the KLF2a over expression and <italic>ccm2</italic> CRISPR experiments are random. Similarly, the abundance of over-expressed KLF2a per cell is also random. Thus, frequencies of CVP dilation can vary between the two approaches.</p><disp-quote content-type="editor-comment"><p>Is the level of overexpressed klf2 in the range reached by klf2 after ccm2 deletion?</p></disp-quote><p>As mentioned above, there is considerable variability in the quantity of KLF2a over-expressed in each cell. Furthermore, there is no easy way to compare the over-expression of mOrange-KLF2a with the increase in KLF2a promoter-driven GFP expression in the <italic>ccm2</italic> CRISPR experiment.</p><disp-quote content-type="editor-comment"><p>Where is this overexpressed klf2 actually localized? Is this overexpressed klf2 localized in the pillars of the vascular malformation? Is the endogenous klf2 upregulated in the pillars of the vascular malformations of ccm2 Crisp embryos?</p></disp-quote><p>We have no access to an antibody against fish KLF2a that could be used for this purpose.</p><disp-quote content-type="editor-comment"><p>4. Do the malformations contain ccm2 null endothelial cells? No direct evidence is presented, besides the rescuing of the dilated CVP phenotype by ccm2-mRNA. Do the lesion-free areas of the Caudal venous plexus contain equal density of ccm2 null endothelial cells as in lesion areas?</p></disp-quote><p>In the transient over-expression of KLF2a and in <italic>ccm2</italic> CRISPR experiments, we did not have antibodies available to visualize the CCM2 and KLF2.</p><disp-quote content-type="editor-comment"><p>5. Statistical analysis needs be shown to support the reproducibility of the data presented in Figure 3 E and F. Which was the range of reduction of vein diameter after pillar ablation and how many embryos were used to reproduce this result? This aspect needs to be strengthened has much of the model interpretation is based on the role of intraluminal pillar in obstructing blood flow and causing vessel dilation.</p></disp-quote><p>We report: âIn 3 such independent experiments, severing these pillars resulted in a 29Â± 4% reduction in vessel diameter (p=0.0004, two-tailed T test).â</p><disp-quote content-type="editor-comment"><p>6. In several figures presenting morphologic data statistical analysis is missing and should be added. Figure 6A, B, C quantification of the immunofluorescence results is lacking. How many endothelial cells show upregulation of klf2 in ccm2 Crisp? No control of Figure 6B is shown.</p></disp-quote><p>We have added statistical analysis throughout the paper. In response to referee 2 we have relocated the KLF2a reporter data to Figure 4 in the revised paper. In Figure 4F we now show a quantitative analysis of reporter expression that documents the mosaic upregulation of KLF2a in <italic>ccm2</italic> CRISPR fish relative to controls.</p><disp-quote content-type="editor-comment"><p>7. How would erythrocytes contribute to the formation/dilation of the cavernae? Would this be a mechanical effect or would erythrocytes convey other signals to endothelial cells? Are erythrocytes present in the cavernae ccm2 null?</p></disp-quote><p>Nucleated erythrocytes, ~8Î¼m in diameter, are trapped in the meshwork of intussusceptive pillars, wherein plasma can still circulate. In addition, by increasing the viscosity of blood, erythrocytes can contribute to the shear forces that drive intussusception.</p><disp-quote content-type="editor-comment"><p>8. It is not clear what come first: both erythrocyte null and heart-silenced ccm2 crisp show reduction of dilated CVP. Do erythrocytes circulate in silenced heart Z. fish?</p></disp-quote><p>When the heart is stopped, blood circulation ceases.</p><disp-quote content-type="editor-comment"><p>9. Are the embryos developing malformations in the CVP surviving? If yes, are the cavernoma in the Caudal venous plexus persisting?</p></disp-quote><p>We note (e.g. Abstract line 3) that we are describing a ânovel lethal multi-cavernous lesion in the embryonic caudal venous plexus (CVP).â</p><disp-quote content-type="editor-comment"><p>10. When and how do the cavernomas form in the brain of the surviving fishes? This is a significant aspect to define in this model, as cavernomas in the central nervous system are the malformations with pathological consequences in humans. How long do these mutant adults survive?</p></disp-quote><p>Lesions form in the brain by 6 weeks post fertilization. Unfortunately, at the stage, the zebrafish are no longer transparent so we cannot easily observe the process in real time.</p><disp-quote content-type="editor-comment"><p>11. In murine models klf4 is also required for cavernoma formation. Is the same true for Z. fish?</p></disp-quote><p>We found that a published KLF4 morpholino did not prevent CVP dilation in <italic>ccm2</italic> CRISPR fish (Reviewer Figure) and mention this result in the discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[â¦] 1. I understand why the adult phenotype is presented, and it does show validity of the adult fish as a model. However, in terms of mechanism, it raises interesting questions that were not adequately addressed â for example, how do lesions form in a tissue that is not known to undergo intussusceptive angiogenesis? Is Klf2 expression also mosaic in the adult fish brains? Can the fish be used to generate mosaic Klf2 over-expression and determine effects in the adult independent of CCM2 manipulation?</p></disp-quote><p>We agree that the question of whether the mechanism we have observed in the CVP occurs in the brain is of great interest. That said, because we cannot visualize development of the brain lesions in real time, we cannot establish this point. Similarly, generating a mosaic KLF2a expressing adult fish would be a useful experiment. That said, since the loss of <italic>klf2a</italic>, completely inhibited adult CCM formation, this time consuming experiment is not urgent and is beyond the present scope.</p><disp-quote content-type="editor-comment"><p>2. Many of the statements regarding the data in the Results and Discussion are stated as facts rather than presented as conclusions â there are too many to enumerate, but examples: p. 18: &quot;first zebrafish model of CCM&quot;.</p></disp-quote><p>We have removed any reference to âthe firstâ (e.g. in the Abstract).</p><disp-quote content-type="editor-comment"><p>p. 19: &quot;pillars failedâ¦to split due to mosaic over-expression of klf2aâ¦.&quot;. The work is very rigorous but all experiments have caveats. The Discussion is also very focused on why the adult fish is a good model for clinical CCM, and many interesting aspects of the bulk of the work presented in the embryo are not addressed. For example, why is mosaic loss but not global loss of flow-sensing proposed to lead to the phenotype?</p></disp-quote><p>We have addressed this important question at several point in the Discussion with respect to perturbed flow signaling and with respect to mosaicism.</p><disp-quote content-type="editor-comment"><p>Are the mechanisms the same in vessel beds that do not undergo intussusceptive angiogenesis? What is the effect of the CCM complex vs. CCM2 alone?</p></disp-quote><p>We indirectly addressed this issue by showing that over-expression of wild type <italic>ccm2</italic> but not <italic>ccm2(L197R)</italic> cause CVP dilation (Figure 6B and Bâ). CCM2(L197R) does not bind KRIT1 and is therefore not incorporated into the CCM complex.</p><disp-quote content-type="editor-comment"><p>3. The work is quite novel and exciting; however, it is difficult to keep track of the different manipulations and combination of manipulations, and this is exacerbated by very poor labeling of figures and descriptions in figure legends. Many of the Y-axis labels merely say &quot;% phenotype&quot; with no context for complex combinations of manipulations. Images are not well labeled for stains/reporters. There is no documentation that most experiments were mosaic for deletion, which is central to the model put forward â the labels suggest global LOF. Suggest use (or figure out if this is new) a nomenclature for mosaic deletion and use consistently. Please be clear about GOF vs. LOF manipulations.</p></disp-quote><p>Thank you for this comment. We have revised the paper and changed all of the ordinates to clearly state the phenotype..</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[â¦]</p><p>1. Do actin stress fibers form and/or does pMLC increase in endothelial cells of lesions? This would highlight conservation of CCM lesion mechanisms between fish and human.</p><p>2. Since the authors have previously shown that inhibition of Rho kinase can suppress lesion formation in mouse models it would be nice to see if this is also true in their mosaic zebrafish model.</p></disp-quote><p>We now report (Figure 7âfigure supplement 2) that, like mammalian CCM, inhibiting Rho kinase blocks development of the zebrafish CVP lesion.</p><disp-quote content-type="editor-comment"><p>3. While the authors show that mosaic overexpression of klf2a is responsible for the formation of vascular defects in the CVP of ccm2 mosaic fish, they do not show this when Ccm2 is overexpressed (Figure 5B). Therefore, they should inject linearized ccm2 fused to mOrange into the klf2a mutants to see if these embryos also fail to develop CVP dilations.</p></disp-quote><p>We report that there is a marked reduction CVP dilation when ccm2 is over expressed in klf2a mutants (Figure 6âfigure supplement 1)</p><disp-quote content-type="editor-comment"><p>4. In the text the authors state that CCM lesions were not observed when ccm2 was edited in klf2a-/- mutants, but in Figure 7P they report 1/10 embryos with lesions. The text should be amended to reflect this result, as it misrepresents their conclusions.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>5. There has been a bit of controversy in the zebrafish community regarding the use of &quot;Crispants&quot; and morpholinos versus germline mutants that the authors should acknowledge (ie PMID: 32968253). I have no issues with the interpretation of data in this study since they performed rescue experiments but given the differences in phenotypes compared with germline mutants this needs to be discussed.</p></disp-quote><p>We agree that this is an important issue and stress that the <italic>klf2a</italic> loss of function experiments were performed on both mutants and morphants. Secondly, the CVP dilation phenotype was rescued by re-expression of CCM2 (Figure 1G), thus controlling for off target effects of CRISPR.</p><disp-quote content-type="editor-comment"><p>Reviewer #4:</p><p>[â¦] â I am not convinced that this model is better than the mouse models available. It is a complex, time limited and variable condition. The percentage of fish resulting affected is relatively low and this prevents the use of this model for high throughput screening of thousands of compounds, as proposed by the authors.</p></disp-quote><p>We have now modified the final paragraph of the discussion to remove any implication that this phenotype could be used for high throughput screening while emphasizing its potential utility in targeted genetic or pharmacological analyses. We suggest that the fish model has unique virtues as argued in the last paragraph of the discussion.</p><disp-quote content-type="editor-comment"><p>â Not all the conclusions are substantiated by previous work in the mouse. For instance, the authors underline that klf2a is the major effector of cavernoma formation in the fish, while in mice klf4 is equally or even more important.</p></disp-quote><p>We have not been able to substantiate a role for KLF4 in the zebrafish CVP lesion (Reviewer Figure) and have so stated in the paper. We were unaware of data showing that KLF4 in more important than KLF2 in the mammalian CCM or that either was essential for human CCM.</p><disp-quote content-type="editor-comment"><p>â Most importantly, there are no data showing that the formation of pillars and abortive angiogenesis also occur in CCM2 deficient mammals.</p></disp-quote><p>True, since the paper is describing zebrafish models.</p></body></sub-article></article>